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In a prospective study, 50 children with congenital cytomegalovirus
(CMV) infection were followed up for periods of one to three years.
Thirty two infants were born following maternal primary infection, ten
following maternal recurrent infection and the type of infection could
not be defined in eight cases. Three (6%) were symptomatic in the
neonatal period, two with neurological abnormalities, one with
pneumonitis. In the first six months of life, two suffered transient
hepatosplenomegaly, and six (12%) pnuemonitis. Six (12%) suffered
long-term sequelae, one spastic quadraplegia with optic atrophy, one
spastic quadraplegia with sensorineural deafness and four sensorineural
deafness alone. In three cases (6%) deafness was bilateral and hearing
aids were required.
There was no evidence that congenital CMV caused mental retardation,
intrauterine or postnatal growth retardation, in the absence of
neurological abnormalities. Children with microcephaly or symptomatic
in the neonatal period had a poor prognosis. No other indicator
including type and timing of maternal infection, titre of CMV specific
IgM in cord blood, persistence of viral excretion, or maternal socio¬
economic background was associated with poor outcome.
Women under twenty years, black women and single women were
significantly more likely to give birth to a congenitally infected
infant than white, married women over 25 years with a relative risk of
3.9, 2.1 and 2.5 respectively.
- 3 -
ACKNOWLEDGEMENTS
This work was performed as part of a study of the epidemiology of
cytomegalovirus infection in pregnancy in the Department of Community
Medicine and General Practice, Charing Cross Hospital Medical School
under the supervision of Dr. C.S.Peckham. I owe an enormous debt to her
for her guidance and support while performing this work. I also wish to
acknowledge the help of other colleagues. Audiological assessments were
performed by Dr. Bethan Davies, Dr. Clare Barttlet and Dr. Geoffrey
Heron. The Griffiths Developmental Assessments were performed jointly
with Dr. K.N.Pearl and some of the children were examined by Drs.
J.Davies, E. Ross, C.S. Peckham. Virus culture and maternal serology
were performed by K.S.Chin, CMV specific IgM tests were performed by Dr.
P.D.Griffiths and D.N.A. endonuclease typing by Dr.J.Garret. The data
was analysed with the help of Mr.R.Bond and his staff of the Dept. of
Medical Commputing, Charing Cross Hospital. Statistical analyses were
performed by Dr. A.Ades. I also acknowledge the valuable contribution to
this study of Research Assistants Pat Tookey, Kathy Henderson and
Gillian West. Printing was kindly performed by Business Computer
Projects Ltd, Stockport.
This study was supported by grants from the Medical Research Council
and Action Research for the Crippled Child.
Statement of originality:







Rates of congenital CMV and prevalence of maternal CMV
antibody. 2
Frequency of intrauterine transmission of primary
maternal CMV infections. 2
Prospective studies of congenital CMV infection. 2
Prevalence of deafness in children with congenital CMV,
symptomatic at birth. 2
Prevalence of deafness in children with congenital CMV,
asymptomatic at birth. 2
Congenital CMV: effect on intelligence. 3
Maternal CMV infection and relation to subsequent
outcome in children with congenital CMV. 2
Method of diagnosis of 50 children with congenital CMV
infection. <\
Type and timing of maternal infection in 50 cases of
congenital CMV. L
10. Comparison between children with congenital CMV and
control children.
11. Maternal factors in children with congenital CMV and
controls.
12. Intrauterine growth of children with congenital CMV and
controls.
13. Features noted in the neonatal period in children with
congenital CMV and controls.
14. Follow-up of children with congenital CMV,number
examined at each age.
15. Children with CMV and controls; abnormalities noted at
each examination.
16. Hearing assessments in children with congenital CMV and
controls.
17. Developmental quotient of children with congenital CMV
and controls.
18. The effect on a child's developmental quotient of
individual variables.
19. Tests of motor coordination in children with congenital
CMV and controls.
20. Developmental testing using the Stycar scoring sytem;













21. Standard deviation score (SDS) of weight, length and
head circumference (HC) of congenital CMV and controls. 58
22. Clinical manifestations at birth and at subsequent
follow-up of children with congenital CMV and controls. 60
23. Outcome in congenital CMV in relation to maternal
characteristics. 60
24. Outcome of congenital CMV in relation to type and
gestation of maternal CMV infection. 60
25. Outcome of congenital CMV in relation to features noted
at birth. 60
26. Outcome of congenital CMV in relation to persistence of
viral excretion. 61
27. CMV specific IgM titre in relation to gestation and
type of maternal CMV infection. 61
28. Outcome of congenital CMV in relation to CMV specific
IgM titre in cord blood samples. 61
29. The estimated prevalence of congenital CMV infection by
maternal characteristics and infant sex. 61
30. Congenital CMV by maternal race, marital status and age;
rate per 1000 live births. 62
31. Risk of congenital CMV related to maternal age, race
and marital status . 62
32. Type of maternal CMV infection resulting in congenital




Fig 1. Prevalence of congenital CMV infection and CMV
antibody by age in different countries. 19
Fig2. Adjusted mean Griffiths Developmental Quotient of
children with asymptomatic (no sequelae) and
symptomatic (neurological sequelae) congenital CMV
compared with mean of controls. 56
Fig 3. STYCAR test scores on control children. 57
Fig 4. STYCAR test scores of children with congenital CMV
compared with the mean of controls. 57
Fig 5. Adjusted mean Standard Deviation Score of head
circumference and birth weight of children with
congenital CMV with no sequelae and neurological
sequelae compared with the mean of controls. 59
Fig 6. Adjusted mean Standard Deviation Score of length of
children with congenital CMV with no sequelae and
neurological sequelae compared with the mean of
controls. 59
Fig 7. CMV antibody status of 8057 women at their first
antenatal attendance. 63
- 8 -
Fig 8. Pattern of CMV infection in families with a
recognised source of CMV (I). 63
Fig 9. Pattern of CMV infection
recognised source of CMV
Fig 10. Oligonucleotide patterns
infant of family 6.
Fig 11. Oligonucleotide patterns
7 and 8.
in families with a
(II). 63
of CMV DNA from mother and
63




1. Maternal details. 121
2. Infant details. 122
3. Master card. 123
4. Infant record. 124
5. STYCAR record form. 130
6. Tests of coordination. 139







































Lymphocyte transformation (proliferation) response





Special care baby unit
Standard deviation score
Small for gestational age




Human cytomegalovirus (CMV) infection is world wide and
present in all communities studied. This virus appears to have
developed a symbiotic relationship with man and in the majority of
individuals infection causes no disturbance to the health of the
host. In circumstances where the host defence mechanisms are
suppressed or immature this organism becomes pathogenic. This
occurs in patients undergoing transplant surgery and in premature
neonates. In this thesis the effect of intrauterine CMV on the
fetus is explored together with the consequences of congenital CMV
infection on affected children.
1, HISTORICAL BACKGROUND
At the beginning of this century intranuclear inclusion bodies
were seen, at post mortem examination, in salivary glands of
infants who died in the neonatal period. 92,117,155,169 It was
felt that these infants may have had a protozoal infection and
Smith 181 suggested the organism be named Entamoeba mortinataliurn.
These lesions were again noted by Goodpasture and Talbot 6(5
in a six week infant, who died with bronchopneumonia; lesions were
found in lung, kidney and liver. They coined the name
"Cytomegalia" and suggested that the lesions were distinct and
pathognomonic of a specific disease entity but questioned the
protozoal origin. Viral etiology was suggested by Von Glahn 223
and proven, for the guinea pig form, by Cole and Kuttner 28,by
transmission of the disease from material passed through a
Berkefield N filter.
McCardock and Smith 123 and Smith and Vellios 183 presented a
total of 46 autopsy reports of infants in whom intranuclear
inclusions were seen, not only in the salivary glands, but also in
other organs. Wyatt et al 235 reported a further six cases and
reviewed all the previous case reports. They suggested viral
etiology was likely in view of the similarity of the pathology to
that found in mice infected with murine "Salivary gland virus".They
also suggested that the inclusion bearing cells were pathognomonic
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of the condition which they called "cytomegalic inclusion disease".
Despite evidence from Farber 5^1 that these lesions were present in
12% of routine autopsies, Wyatt et al 235 considered that the
condition was inevitably fatal. This theory was discounted by the
observation of intranuclear inclusion bodies in epithelial cells in
urine of non-fatal cases. 52,119,132
The possibility of investigating the true significance of CMV
infection was realised, with the development of cell culture
techniques, 50 and the isolation of murine CMV. 184 In 1956 human
CMV was isolated simultaneously in three separate centres.
172,185,226
2. CYTOMEGALOVIRUS
The Herpes group of viruses include Herpes Simplex virus,
Varicella Zoster virus, Epstein Barr virus and CMV. The common
characteristics of the herpes group are their icosahedral (20
sided) shape, containing DNA and the ability to cause intranuclear
inclusion bodies. 230 All Herpes group viruses exhibit the
potential to establish latent infections. The morphology of CMV
has been described by Wright et al 234 and the specific
characteristics described by Weller 228 and further defined by
Matthews. 121
3. DIAGNOSIS OF CMV INFECTION
The most reliable method of diagnosis of CMV infection is by
virus isolation in cell culture. This has replaced identification
of inclusion bodies in cells in urine which is less reliable. 52^
The technique of cell culture is fully described by Albrecht and
Weller. 7^ Briefly 0.2 mis of fresh urine are inoculated into
culture medium, in tubes containing a monolayer of human fibroblast
cell culture. The tubes are then incubated for up to four weeks
and inspected at regular intervals for evidence of the typical
appearances of cytopathic effect (CPE). The sheet of elongated
fibroblast cells show foci of enlarged, rounded cells with
intranuclear inclusions. These foci then coalesce. The foci may
appear between three days and two weeks incubation. CMV has been
isolated from most body fluids, including urine, saliva, tears,
breast milk, faeces, semen, lymphocytes and cervical secretions.
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30,31,32,86,101,112
Because of the time required for isolation by cell culture,
attempts have been made to develop more rapid diagnostic
techniques. Schmidt and Gal 1 o 178 developed an immunof1uorescent
technique whereby labelled antibody is introduced into cell
cultures early to fix to CMV infected cells and so detect presence
of the virus before CPE appears. Other similar techniques have
recently been developed. 64,114,162
Alternatively, samples with high viral titres have been
examined by electromicroscopy and virus has been detected in 90% of
samples positive to CMV by cell culture. 114,118 This technique
is of value in infants, less than six months old, who excrete large
quantities of virus, but is less useful in older infants where the
sensitivity falls to 45%, as most infants over this age excrete
If
virus in titres of <10 organ isms/ml. 114
4. SEROLOGICAL TESTS OF CMV
The complement fixation (CF) test is the most widely used test
to detect CMV antibodies. The presence of CMV antibody
(seropositive) indicates previous exposure to CMV, and may also be
used to detect primary CMV infection by the detection of a rise in
antibody in two samples tested in pair (i.e.seroconversion.) The
technique was first used by Rowe et al 172 and has been fully
described by Lennette and Schmidt. 116 In brief, CMV antigen,
prepared from CMV positive cell cultures usually of strain AD 169,
33 is incubated with patient serum containing antibody, binding
complement in this reaction. The remaining, unbound, complement
then acts as an indicator of the degree of complement fixation by
lysing sensitive sheep red cells. Stern and Elek 207 have shown
cross-reactivity with many strains of CMV and Starr et al 204 have
demonstrated no cross-reactivity with other viruses, except
occasionally with other herpes viruses. 228 While individual
titres of antibody may vary considerably with time, 224 Starr et
al 204 have demonstrated that the titres remained positive (>1:4)
in 19 of 21 children studied (76/78 tests) over a three year
period. The major criticism of the CF test is its lack of
sensitivity. This has led to the development of other techniques
for the measurement of CMV antibody 70,160.
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Indirect immunofluorescence (IF), 81,192 enzyme-linked
immunosorbent assay (ELISA) 61,62 and radioimmune assay (RIA)
97,100 have been developed. All three tests have an enhanced
sensitivity when compared with the CF test 70 but for routine
screening and population studies it is debatable whether any one
test is more valuable. 20,61,70,100,192
The major advantage of the newer tests is their ability to
measure CMV specific IgM antibody which generally does not fix
complement except in specific circumstances. 21^ This is
important for the diagnosis of congenital infection since IgG
antibodies freely cross the placenta; so the CF test in the
neonatal period will measure not only infant but also maternal
antibodies. 73,192 Many viral infections are associated with a
rise in IgM antibody levels in the acute phase of the illness. 96^
The detection of CMV specific IgM has also been used to detect
recent primary CMV infection. 91_ All three methods of detection of
IgM antibody have been used in both situations and a new method of
IgM capture (MACRIA) has recently been described. 213
The sensitivity and specificity of the IF test appears to vary
depending on the study. Ahlfors 4^ found that 91% of primary
infections, identified by seroconversion, were associated with
raised IgM by IF, whereas other studies have identified only 60-69%
by this technique. 69,74,85 In addition, false positive
reactions are frequent. 42,74 Macroglobul in has also been
associated with reactivation of CMV, and can be demonstrated in low
titre intermittently for years using this assay. 100,179
Evaluation of solid phase RIA has demonstrated that this
method will identify 86% of infections within four months of the
primary infection 74- and is not positive in recurrent infection
except in the immunosuppressed patient. 98,164 The period of
persistence of IgM antibody, detected by ELISA in primary
infections, has not been defined. 222,243 Although no direct
comparisons are available between solid phase RIA and MACRIA or
ELISA the sensitivity of each test is thought to be similar.
Similar problems have been encountered in the diagnosis of
congenital infection using the IF techniques, with a 50-70%
sensitivity rate, compared with virus isolation, 69,131 rising to
96% in symptomatic infants. 82 It is also associated with a high
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false positive rate. 196 Solid phase RIA, however, is 93%
sensitive, identifying 100% of symptomatic infants and 87% of
asymptomatics. 7!5 The higher titres in symptomatic infants has
led to attempts to predict those infants with a poorer prognosis
using the level of IgM titre. 75^ The ELISA technique has also
been successfully adapted for use in this situation. 170
5. GENETIC VARIABILITY OF CMV
Serological tests of CMV antibody do not distinguish between
individual strains of virus. 207 This has meant that it is not
possible to prove epidemiological associations between related
cases particularly in nosocomial infections. DNA endonuclease
typing however will allow distinction to be made between strains.
The technique was first described by Huang et al. 9jL They
demonstrated many different strains of CMV and identical strains
only in viruses isolated from related cases, such as mothers, and
their congenitally infected infants. They have also demonstrated
minor genetic differences in viruses grown in cell culture over
long periods. This technique has been further modified to allow
application to samples with much lower virus titres. 56,219
6. CELL MEDIATED IMMUNITY (CMI) TO CMV INFECTIONS
Cell mediated immunity to viral infections is complex. It
probably acts as the main defence mechanism against viral
infections in humans. In CMV infection the numbers of T
lymphocytes are normal and the measures of CMI to other antigens
such as Herpes Simplex virus or PTA are normal. Interest was
aroused by the use of CMV specific lymphocyte proliferation
response (LTR) by Gehrz 5T7 as a measure of the competence of the
CMI to combat CMV. This measure is mediated by T memory cells and
results in their transformation to produce T and B lymphocytes
which react with CMV antigen. 24 Pollard 159 has demonstrated
that 90% of subjects, seropositive to CMV, have a positive LTR to
CMV antigen. These studies have demonstrated that the LTR is
suppressed or absent in the first few years of life in infants with
congenital or neonatal ly acquired CMV. 60,143,147,148,168
This suppression is transitory and LTR function is restored to
normal by four years of age, which coincides with the subsidence of
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viruria. 206 A similar depression of LTR occurs in the last
trimester of pregnancy and persists for three months postpartum.
59 This is not just in women who have CMV positive infants. No
defect has been demonstrated in lymphocyte migration inhibition
test 5L3 and lymphotoxicity assay. 171 Although the total T cell
count is not reduced, the ratio of specific type T cells is altered
in congenital and acquired CMV with a decrease in T8 (Suppressor)
cells in infants under one year and restoration of
Helper/Suppressor ratio in infants over one year. 149 The effect
of these changes is not clear. The changes are similar in
children with symptomatic and asymptomatic forms of congenital CMV
and in post-natally acquired infection. 148 The suppression of
LTR in pregnancy may allow CMV to reactivate and cross the placenta
but this does not always occur. 59^ The tests of lymphocyte
function investigated to date may not be evaluating the critical
steps in the cell mediated immune system which determine the
presence or absence of viral replication, when replication may
occur, and whether infection crosses the placenta.
7. EPIDEMIOLOGY OF CMV INFECTIONS
The epidemiology of CMV infection in Man is extremely complex
and despite extensive study still not fully understood. The
development of the CF test for CMV antibody by Rowe et al 172
allowed the prevalence of CMV infection to be studied. Since
antibody persists for many years, the detection of antibody is a
measure of previous exposure and so the percentage with detectable
CMV antibody (seropositive) in the population rises gradually with
increasing age. Rowe et al also observed a general trend to
higher seropositivity rates in women compared with men.
Since these early studies, the prevalence of CMV
seropositivity has been investigated worldwide and CMV antibody has
been found in all populations studied. 17,102 These studies,
summarised by Krech et al 102 showed a prevalence of antibody in
adults approaching 100% in countries such as India, Uganda, Ivory
Coast, the Caribbean Islands and Fiji, whereas prevalence rates of
40-60% were reported in Britain, USA, France and Germany. Other
affluent countries, however, also have high seropositivity rate
notably Japan (93%), Italy (97%), Czechoslovaka(92%), Finland(85%)
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and Sweden (73%). 4 It is not apparent why there are these wide
variations between countries, particularly where the populations
are similar, such as Britain and Finland. Wide variations also
occur, not only between populations, but between different
subpopulations. 201,208
All the studies reported refer to pregnant women and there is
a direct relation between the prevalence of antibody in pregnant
women and the acquisition of antibody by children up to four years.
102 This is demonstrated in Fig.l, where it can be seen that
infection is most rapidly acquired in Japan and Ivory Coast, where
the prevalence in adults is also high, and least rapidly in
Britain.
Acquisition in the first year of life
There is now substantial evidence that the major source of CMV
in young children is their own mothers. In population studies
Granstrom et al 68 identified 51 (32%) children who excreted CMV
in a cohort of 148 children followed for one year. None of the
infants born to the 23 seronegative mothers acquired CMV. Similar
findings have been reported from France, 109 Japan 95^ and Britain.
93 That the virus acquired is of maternal origin is proved by
DNA endonuclease typing, which shows identical strains of virus
isolated from mother and baby. 154 There are two major sources of
infection; that acquired at birth by passage through an infected
birth canal, and infection acquired from breast milk. In healthy
women CMV is more frequently recovered from cervix than any other
site. Isolation rates of up to 15% have been reported.
101,137,193 High isolation rates have been related to lower
social class and young maternal age. 101,137 Montgomery et al
137 also reported isolation rates increased in pregnancy towards
the third trimester but Stagno et al, 193 using nonpregnant
matched controls, demonstrated that the isolation rates were
suppressed in early pregnancy and actually increased to
prepregnancy levels in the last trimester.
Infants who acquire CMV during delivery do not start to
excrete virus until after an incubation period of at least 21 days.
166 Thus congenital and acquired infection can be distinguished.
In a study by Stagno et al , 193 acquisition of virus was more
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Prevalenceofcong italCMVinf ctiona dn bodybye differentcountries. FIG1.
frequent in infants of mothers who excreted virus from the cervix
in the last trimester and post term (57%) compared with those who
excreted virus in trimesters I and II (12.5%).Infants of women who
excreted virus in urine and saliva only, but not from the cervix,
did not acquire CMV in this study 193.
Breast milk is the other common source of infection. Hayes
et al 8J5 isolated CMV in 27% of samples of breast milk from
seropositive women. The frequency of isolation was higher in
breast milk after one week than in colostrum samples. 197 In a
study of the infants of 396 mothers, 197 57% acquired CMV when
breastfed by mothers whose breast milk was known to contain virus.
None of the nine bottle-fed infants acquired the infection, despite
active maternal infection. The rate of acquisition was most rapid
in the first six months of life and declines after this age.
68,109,142
CMV may also be acquired in the neonatal period from sources
other than the mother. Nosocomially acquired infection occurs,
though it has not been possible to document cross-infection in
neonatal nurseries. One incident investigated by Gurevich et al
79 was heavily criticised as no DNA typing was performed, and
other, more likely, sources of infection were not excluded. 189
Spector, 190 however, has recently investigated seven cases of CMV
infection in a neonatal unit using DNA endonuclease typing. Three
babies were infected with an identical strain from either the same
source or spread within the nursery. Cross-infection was not
universal as four other babies, with temporally related acquisition
of CMV, were found to be infected with four different strains.
Blood transfusion is a more frequent source of acquired CMV
infection in neonatal units. 237 This was confirmed in two
studies 14,145 where CMV was acquired by 16-35% of infants given
blood with CMV antibodies but less than 7% acquired CMV if CMV
positive blood was not used. The remaining infections were
presumably maternally acquired. Neonatal infection is usually
symptomless and of no clinical significance, but when acquired by
ill or very low birth weight infants CMV can result in acute
illness with lymphocytosis, hepatosplenomegaly, respiratory
distress and death. 12,236
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The rate of CMV infection was similar in infants of
seropositive mothers irrespective of blood transfusion. 240 Of
74 seronegative infants, however, 13.5% receiving seropositive
blood acquired CMV but none of those receiving seronegative blood
acquired infection. The rate was also related to the volume of
blood given. Acquisition of CMV by this route is more serious for
infants of seronegative mothers because of the lack of CMV
antibodies acquired by passive transfer. Even infants, who are
under 1500g, of seropositive mothers, are at risk of serious
sequelae from CMV because of the rapid fall in titre of passively
aquired CMV antibody due to catabolism and blood sampling. 242
Acquisition in older children.
Acquisition of CMV in older children may be from sources
outside the family. Since infants with both congenital and
postnatally acquired CMV excrete large quantities of virus for
periods of up to four years, 192 siblings or play contacts provide
multiple sources of infection once children become mobile and start
to mix with other children outside the home. Children who attend
day nurseries acquire CMV infection more rapidly than children
cared for full time in the home. 150 In studies from Alabama,
151 in a white, middle class, population, only 10% of infants
under one year were excreting CMV, but this rose to 78% between one
and two years in those cared for full time in a day nursery
compared with only 18% of similar children cared for at home.
Further evidence comes from a study of Israeli children from three
different communities. 176 Using serology to assess the
frequency of infection, there was a steep rise in seropositivity in
urban children when they first attended day nurseries, and this was
exacerbated by overcrowding. In bedouin children, however, who live
in isolated seminomadic communities until they start school, the
prevalence of antibody rises steeply at five years. Children in a
kibbutz, however, were subjected to a communal care system from
about six months and, in consequence, acquired CMV much earlier
than either urban or bedouin children.The prevalence of antibody
gradually rises in later childhood and is probably influenced by
exposure to siblings and class mates leading to higher rates of
acquisition in institutions. 207
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In contrast with congenitally infected children, post natally
acquired CMV is not associated with serious neurological handicap,
although transient illness such as hepatosplenomegaly and
pneumonitis may occur. 80,108
Acquisition in young adults
Circumstantial evidence suggests that sexual transmission is a
common mode of transmission in young adults. This is based on the
rapid rise of seropositivity in the teenage years. 39 CMV is
frequently found in association with patients attending sexually
transmitted diseases clinics, 94 and very high rates of antibody
are found in homosexual men. 4!) CMV mononucleosis has been
reported following sexual contact 27,110 and CMV has been cultured
from semen 112 while higher rates of isolation from the cervix are
reported in teenage girls with rates decreasing with age. 101
Finally the rise in antibody levels, seen in young adults, does not
occur in nuns working as nurses or teachers. 39
Epidemiology of CMV infection in pregnancy and its relationship
to rates of congenital CMV.
The prevalence of congenital CMV varies from 0.24% to over 2%
of live births depending on the population screened (Table 1).
There is a general trend for high rates of congenital infection to
be associated with high seropositivity rates in the adult
population. In England, 127 Denmark, 9^ and Canada, 113 where
rates of congenital infection of 0.2-0.4% of live births are
reported, the prevalence of antibody in the adult population is
low. In developing countries such as Chile 202 and the Ivory
Coast 180 and disadvantaged subpopulations in the USA, 201 where
adult seropositivity rates range from 82-100%, rates of congenital
infection of 1.4-1.7% of all live births are reported. This
suggests that poor social circumstances lead to an increase in both
congenital CMV and adult CMV infection. However, this is not
always the case. High rates of both congenital CMV and adult sero¬
positivity are seen in economically affluent Finland, 68 whereas
in Japan and Sweden there is a low rate of congenital infection
despite very high seropositivity in mothers. 5,95 Thus the
relationship between the prevalence of congenital infection and the
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prevalence of maternal seropositiviity is more complex than it at
first appears.
The rate of primary infection in pregnancy varies and is
reflected by the rise in the prevalence of antibody during the
childbearing years. 69,71,208 Rates of seroconversion during
pregnancy vary from 0.6-4.0%. The average rate of seroconversion
in pregnancy in serosusceptibles in published studies is 1.1%. 200
In communities with high seropositivity rates, the chance of
seroconversion for the remaining serosusceptibles may be high.
Fetal infection occurs in about half of these cases studied, though
it is not yet possible to predict which infections will be
transmitted in utero (table 2).
In the early studies it was assumed that previous maternal
CMV protected the fetus from congenital CMV. 208 The finding
that congenital CMV could occur in consecutive siblings
demonstrated that reactivation of latent infection or reinfection
could result in intrauterine infection. 4-9 Huang et al 9^
demonstrated, using DNA endonuclease typing, that the infection in
a pair of congenitally infected siblings was due to infection with
genetically identical virus in both infants. This suggested that
infection in the second pregnancy resulted from reactivation of
latent virus, not reinfection with a new strain. This type of
infection is now referred to as a recurrent maternal infection.
In communities with high rates of congenital CMV the majority of
cases of congenital CMV result from recurrent maternal infection.
95,180,202 This has been confirmed by Stagno et al 194 who
report a rate of congenital CMV of 1.9% in a study of women known
to be seropositive prior to pregnancy. The overall rate of
congenital CMV in the community was 2.2%
The overall rate of congenital CMV therefore depends on the
rate of primary maternal infection as well as the rate of recurrent
infection during pregnancy. The distinction between the relative
contribution of each type of maternal infection to the rate of
congenital infection is difficult. It is rarely possible to
obtain preconceptual blood specimens to exclude an early primary
infection in women already possessing antibodies to CMV when
presenting for antenatal care. Grant et al 69 and Stern and
Tucker 208 found no congenital infections following recurrent
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TABLE 2.










Monif 136 604 4(0.6) 4(100)
Stern 209 270 11(4.0) 5 (45)
Grant 69 1841 13(0.7) 5 (38)
Kumar 106 1404 14(1.0) 7 (50)
Giffiths 76 1608 14(0.9) 3/12(25)
Ahlfors 5 1218 14(1.2) 6 (43)
Total 6945 70(1.0) 30 (44)
infection, as judged by the presence of viruria in women who
already possessed CMV CF antibodies. Stagno et al , 201 however,
reported that among a high income group, with a seropositivity rate
of 55%, 53% of congenital infections followed primary maternal
infection and the remainder (47%) followed maternal recurrent
infection. In contrast, in the low income group, with a
seropositivity rate of 82%, only 19% of congenital infections
followed maternal primary infection and 81% following maternal
recurrent infection. In this study, the overall rate of
congenital CMV in the middle income group was 0.6% and, in the
lower income group, 1.6%.
This high rate of congenital CMV does not occur in all highly
seropositive populations. In Japan, 9J[ where all congenital
infections studied resulted from maternal recurrent infection, the
overall rate of congenital CMV is 0.5%, three times less than that
reported in the Alabama study. 201 The different rates of
recurrent maternal infection, resulting in congenital infection,
may in part be accounted for by different age and socioeconomic
structures of the pregnant population. Recurrent infection is
more prevalent in young women, black women, and may also be related
to social class. 101,137 All these are features of the lower
socioeconomic class group studied by Stagno et al 201 and this
could account for the high rates in their study. The lower rates
in Japan could result from differences in maternal age and
socioeconomic status but, unfortunately, the population screened
was not described in detail. In Sweden, 5with a similarly high
prevalence of antibody and low rates of congenital infection, as in
Japan, the proportion of congenitally infected infants whose
infections could be attributed to recurrent maternal infection was
only 36%.
The rate of congenital infection, within a particular
community, therefore depends on the rate of primary infection in
the childbearing years and the overall seropositivity rate. The
age of mothers, their race, socioeconomic status and perhaps
genetic factors, influencing host immune control, will then
influence the frequency of primary infection, recurrent infection
coinciding with pregnancy and the rate of intrauterine
transmission.
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8. PATHOLOGY OF CMV INFECTION
The specific characteristic of CMV is its ability to cause
cytomegalia in infected cells. 89 The affected cells are
characteristically of epithelial origin and are 2-4 times the size
of surrounding cells. They have an eccentrically placed nucleus
which is large (10 -15)Jm) and contain an intranuclear inclusion
(8-10jjm) presenting an "Owl's eye" appearance. These giant cells
may be associated with cellular infiltrate of plasma cells and
lymphocytes. 89^ Intranuclear inclusions of CMV have been seen in
many organs, in biopsy and post-mortem specimens, from children
dying of cytomegalic inclusion disease 183 and in children who die
from other conditions who are coincidental ly infected with CMV. 5^1
Intranuclear inclusions are most commonly seen in the
salivary gland where cytomegaly is confined to the ductal
epithelium. Cytomegalic cells are found in 12% of routine
autopsies jil but appear to be less common in children over 10
years. 216 In the gastrointestinal tract, giant cells may be
seen but may be obscured by the presence of enterocolitis. 183 In
the liver of newborn infants, giant cells are seen in the bile duct
epithelium. There is also extra medullary haemopoiesis and
infiltration of the portal tracts. The liver parenchyma is not
involved. Acquired CMV, giving rise to hepatitis, and
mononucleosis, is associated with mononuclear infiltration without
giant cell formation and good preservation of liver architecture.
19
In the lungs, giant cells are seen in alveolar and bronchial
epithelium. This is one of the most common sites of symptomatic
acquired CMV 188 particularly in infants and the immunosuppressed.
Renal involvement is seen in the interstitium with clusters of
giant cells in the proximal tubules. This is likely to account for
the universal association of viruria with all forms of CMV disease.
Petechial and purpuric skin rashes are sometimes seen in congenital
infection, but vesicular lesions similar to herpes simplex have
been reported. 18 Maculo-papular rashes may also complicate CMV
mononucleosis. 99^
Graham et al 67 noted bone changes in an infant with
congenital CMV, similar to congenital rubella, with linear lucent
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areas between zones of sclerosis in the distal metaphyses ("Celery
stalking"). Spontaneous fractures have also been noted in
severely affected neonates. 187 A specific lesion of teeth has
also been described by Stagno et al 203 with opaque enamel,rapid
wear and severe caries.
Central Nervous System Involvement
Severe congenital CMV is typically associated with CNS
involvement causing microcephaly or hydrocephaly, periventricular
calcification, focal softening, haemorrhages and subependimal
inclusion bodies. 88,183,235 Microgyria due to small abnormal
gyri have also been described. 34- This type of malformation must
develop before the sixth month of intrauterine life. Neurological
involvement is not always obvious in neonates who subsequently
develop neurological handicaps. Bray et al 22 has suggested that
the neurological involvement may be progressive, and describe two
children who had normal or minor changes only on computerised
tomography (CT) which progressed to severe extensive disease over
three months. Although CT scan may demonstrate abnormalities not
apparent on physical examination and so suggest a poor prognosis,
8 it would be rash to claim absence of CNS involvement on the
evidence of a normal CT scan alone.
Congenital CMV has been associated with several types of
visual defect ranging from anophthalmia, 124 microphthalmia, to
optic atrophy. 513 These lesions may be associated with
peripheral choreoretinitis, or occur alone. Choreoretinitis has
not been described in isolation in an otherwise asymptomatic child
with CMV ,in contradistinction to toxoplasmosis. 195 Peter's
anomaly (i.e. a central corneal defect associated with adhesion of
the lens) has also been reported. 55
Congenital CMV is a major cause of deafness. 195 This is
due to a viral 1abyrinthitis affecting the vestibular and
semi-circular canals and the epithelial cells of inner ear,
resulting in hydrops of the inner ear, 138 but not the organ of
corti. 41 Electronmicroscopy has shown this to be associated
with virus particles _37 and is distinguishable from rubella
labyrinthitis. 210 CMV has been cultured from endolymph. 40
Animal models suggest that virus may invade the inner ear via the
eighth cranial nerve 38 rather than via blood, as is the suggested
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route for rubella virus. Progressive damage may also occur as a
result of congenital CMV infection, as with rubella. 36
9. SPECTRUM OF DISEASE IN CONGENITAL CMV
The majority of children with congenital CMV are asymptomatic
at birth. Initial studies described the natural history of
children presenting in the neonatal period with symptoms of
congenital infection i.e. cytomegalic inclusion disease (CID). It
is now recognised, from prospective studies, that some children
with asymptomatic disease at birth may develop significant disease
in later life
a)Cytomegalic inclusion disease.
Congenital CMV was first suspected in infants with
abnormalities noted at birth, and the majority were only recognised
at autopsy. 123,235 These findings have been fully described by
Medearis. 130 Following the realisation that infants with severe
congenital CMV infection could survive, 119,132 several authors
described series of patients with cytomegalic inclusion disease.
125,146,232 McCracken et al 125 reported on 20 children with
CID. Although two may have acquired infection from blood
transfusion, he was able to comment on the long-term follow-up of
18 children with confirmed CID. Sixteen of 18 (89%) presented with
hepatosplenomegaly, 13 of 14 (93%) thrombocytopaenia and 61% (llof
18) haemolytic anaemia. Nine (50%) presented with evidence of CNS
in volvment.
Pass et al. 146 reported the long-term follow-up of 34
infants with symptomatic congenital CMV, 25 (73%) presented with
hepatosplenomegaly and 19 (56%) with evidence of CNS disease.
Both Pass et al and McCracken et al showed similar results at
long-term follow-up. Mortality was 22% 125 and 29% 146 in each
series. Most deaths occurred in the first year of life and all
occurred in infants with severe CNS disease such as cerebral palsy
and microcephaly. In all but one, evidence of extra CNS disease
had resolved by the time of death. The exception was noted to
have hepatic cirrhosis. 146 Hepatosplenomegaly may persist for
up to four years with a wide range of pathological processes such
as cholangitis and periportal fibrosis. 125 Despite the usually
benign course of CMV hepatitis, one other fatal case of portal
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fibrosis, with oesophageal varices, has been reported. 44 Other
extra CNS manifestations usually resolve spontaneously though
thrombocytopaenia may persist for more than three months. 125
CMV pneumonitis is usually benign. 125 There is one case report
of a 13 month-old child who developed diabetes mellitus associated
with congenital CMV 225 and one of sudden death at five weeks due
to myocarditis in an infant with CID. 212 Extra CNS disease may
not be present at birth, a prospective study by Starr et al 205
noted no children with hepatosplenomegaly at birth but one child
had splenomegaly at six weeks.
A number of studies have suggested an association with
congenital abnormalities. Occasional congenital heart defects
have been noted 15,122,125 and other sporadic malformations such
as imperforate anus, 205 cleft palate and micrognathia reported
125 but no recognisable pattern of congenital defects.
The long-term neurological outcome of symptomatic infants is
very poor. In all three long-term studies 125,146,232 the rate
of major neurological handicaps was very high. Fourteen (60%) of 23
survivors in the Alabama study suffered from spasticity and fits,
seven had normal IQ but deafness, and only two were normal (6% of
total, 9% of survivors.) McCracken et al 125 reported only four
(22%) to be normal at nine years, four suffered from bilateral
sensorineural deafness, and seven (39%) severe psychomotor delay
with spasticity and/or fits.
Williamson et al. 232 followed 17 infants with CID, nine
(53%) suffered from severe CNS disease, a further six, with normal
IQ, deafness, and only two (12%) were normal at four years. The
overall rate of deafness was 65% and choreoretinitis 41%. In
addition three suffered from specific language disorders and four
had learning difficulties despite normal intelligence.
b)Prospective studies of congenital CMV
Table 3 shows the major prospective studies of the prevalence
of congenital CMV. As noted in section 6, there is a wide
variation in the rate of congenital infection depending on the
population studied. The possible reasons for this have already
been discussed. The method of screening may also affect the rate
of detection of cases. Several populations have been screened
several times. Melish and Hanshaw 131 found a tenfold increase
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TABLE 3
Prospective studies of congenital CMV infection.
Diagnostic n.Mothers n.Congenital n.Symptomatic
method. screened CMV(%) at birth(%)
Denmark 9 V.I. 3060 10(0.33) 0
New York 131 V.I. 1963 20(1.0) 2(10)
CMV IgM 1845 2(0.1) 1(50)
New York 83 CMV IgM 8644 53(0.6) 0*
Sweden 1 V.I. 2200 7(0.3) 2(28)
Hamilton 113 V.I. 15212 64(0.4) 4(6)
Cleveland 206 V.I. 2259 26(1.6) 1(4)
Alhabama 167 Total 9100 22(0.24) 0*
IgM
Alhabama 201 V.I. 2698 16(0.6) - 1.
V.I. 1014 16(1.5) - 2.
V.I.- virus isolation
* - symptomatic infants excluded
1. - "middle class"
2. - "lower class"
in prevalence using virus isolation compared with CMV specific IgM
measurement, using IF, on cord blood samples. This method is more
likely to select seriously affected infants 7f> and, indeed, in
this study 50% of infants identified by CMV specific IgM were
symptomatic at birth compared with 10% diagnosed by virus
isolation. 131 Hanshaw et al. 84 re-studied this population with
an improved CMV specific IgM IF test but the rate of congenital
infection was still significantly less than previously noted by
virus isolation.
Similarly, studies in Alabama 167 used increased total IgM as
the screening method. These infants were then re-tested
specifically for CMV by virus isolation. The rate of congenital
infection (0.24) was much lower than that found in the same
population by Stagno et al. 201 The sensitivity of the screening
test will therefore have an effect on the findings of each study
and the rates of handicap identified as a result of congenital
infection.
c)Long-term Sequelae of Congenital CMV
(i )Deafness
The incidence of deafness in children with congenital CMV who
present with symptoms in the neonatal period ranges from 11-65%,
6,125,195,199 with a mean of 28% (Table 4.) All suffer from
moderate to profound deafness and 70% are bilateral.
The highest rate was reported by Williams et al at 65%, 232 and
the lowest in the Collaborative Study at 11%. 127 These major
differences are likely to be due to the criteria used to define
symptomatic infection.
Children with asymptomatic congenital CMV at birth have a much
lower incidence of deafness (Table 5.) The range reported is wide
(14-50%.) The rates are high in some studies where children with
very minor hearing losses are included. In the study by Dahle et
al, the inclusion of three infants who suffered loss at 8KHz only
resulted in an overall rate of 50%. 35^ When only those with
significant deafness, i.e. >50 dB bilateral loss and likely to
require hearing aids or special schooling are included, the rate
falls to 5.5%. The range for all studies, of significant
deafness, is 0-7.8% (Table 5).
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TABLE 4
Prevalence of Deafness in Children with Congenital CMV,
Symptomatic at Birth.
n .CMV Deaths Deafness in survivors
lx 2x Total(%)
McCracken 125 18 4 - 4 4(29)
Pass 146 34 10 3 4 7(29)
Stagno 199 24 - 4 4 8(33)
Williamson 233 17 - 1 10 11(65)
McDonald 127 49 4 - 5 5(11)
Ahlfors 6 15 1 - 3 3(21)
Total 157 19 8 30 38(27)
Note lx rUnilateral deafness
2x :Bilateral deafness
TABLE 5.
Prevalence of deafness in children with congenital CMV,
asymptomatic at birth.
n.CMV n.Deafness Mild(25-55db) Moderate-profound
(%) (>55db)
lx 2x lx 2x(%)
Dahle 35 18 9(50) 3 3 2 1(5.5)
Stagno 195 51 7(14) - 1 2 4(7.8)
Hanshaw 83 40 5(12.5) - 2 - 3(7.5)
Saigal 175 40 6(15) 1 1 2 2(5.0)
Kumar 107 17 4(23) 2 1 1 -(0.0)
Total 166 31(19) 6 8 7 10(6.0)
Note lxrUnilateral deafness
2x:Bilateral deafness
There is some evidence that sensorineural deafness, associated
with congenital CMV, may be progressive. Williamson et al 232
reported three children with mild sensorineural loss, at less than
two years, which progressed to severe bilateral deafness at three
years. Similar findings have been reported by Dahle et al. 36
(ii)Psychomotor Development and Intelligence
The evidence that congenital CMV infection is a cause of
mental handicap is conflicting (Table 6.) Melish and Hanshaw 131
suggested that congenital CMV caused as much mental handicap as
Down's syndrome. This was based on their finding that two infants
identified from a population of 1845 had severe psychomotor delay,
a prevalence of handicap 1/1000 equivalent to the rate of Down's
syndrome in Britain. Congenital CMV may cause severe neurological
sequelae 125,130,146,232 but it is not clear if there is a
specific effect on intelligence in the absence of other
neurological problems. Four prospective studies have examined the
intellectual ability of children with congenital CMV.
83,107,167,175 In two studies 103,107,175 the IQ tests were
repeated on two occasions and there was no difference in the
intellectual abilities of children with congenital CMV and their
matched controls. Both studies had difficulty in matching and
there was a higher proportion of single mothers of poor educational
background amongst the congenitally infected infants than amongst
the controls. This would have made any differences between the
groups even more apparent if CMV had an effect. Both studies also
included a battery of other psychometric, language and behavioural
tests, and neither showed any significant effect of congenital CMV
apart from an increase in conduct disorders in the Canadian study.
175 This was probably related to the matching problems
previously referred to.
Reynolds et al, 167 while not showing a significant
difference in the IQ between congenitally infected infants and
controls, postulated that the results were suggestive of an adverse
effect of CMV, because the mean IQ of congenitally infected infants
was lower than controls. Indeed, this study included one
congenitally infected child with severe spastic quadriplegia. The
only study to demonstrate a significant effect of CMV on
intellectual development is that reported by Hanshaw et al. 83
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TABLE 6.
Congenital CMV: Effect on intelligence.
Test used n.CMV mean age I.Q.CMV I.Q.Controls
yrs.
Kumar 103 Stanford 13 4.0 85.0 86.5
Binet
Kumar 107 WISC/ 17 7.6 89.5 85.9
WIPPSI
Reynolds 167 Stanford 18 3.2 92.0 100.0
Binet
Hanshaw 83 WISC/ 44 3.5) 105.0 114.0*
WIPPSI 7.0) 113.0*
Saiga! 175 Stanford 47 3.0 97.0 100.6
Binet 5.0 107.0 106.5
* Matched controls = 114.0 p<0.025 compared with CMV
Random controls = 113.0
One child with severe cerebral palsy was included in the testing,
which makes it difficult to assess the effect of congenital
infection on intellect alone. Hanshaw predicted "school failure"
on the basis of IQ <90, or abnormal neurological findings including
deafness. 36% of children with CMV were expected to fail at
school compared with 14% of matched controls. However, all those
who were likely to fail were cases and controls from social classes
IV and V suggesting an environmental effect, particularly on those
with an IQ of 80-90.
(iii) Specific Neurological Features
The poor neurological outcome of infants, symptomatic at
birth, has already been discussed. Each study reporting the
outcome of infants who are asymptomatic at birth have described
individual children with microcephaly, spasticity, and fits with
rates varying from 2 - 6.6%. 6,83,103,167,175 More detailed
examination of three symptomatic infants by Williamson et al 232
suggests that they may have suffered from specific speech defects
such as dyspraxia or dysarthria. These authors have suggested
focal damage may have occurred in the motor speech area. Visual
disorders such as optic atrophy and choreoretinitis have been
described, but these are rare and occur in children with other
handicaps due to congenital CMV. 55,124,195 In addition to
deafness, minor vestibular abnormalities have been demonstrated in
otherwise asymptomatic children with congenital CMV.
d)The Relationship of Primary and Recurrent Maternal CMV
on Outcome of Congenital Infection.
In the six prospective studies of primary CMV infection in
pregnancy, 5,69,76,106,136,208 the rate of intrauterine
transmission is about 50%, with two exceptions (Table 7.) In the
study by Monif et al, all of four mothers with primary CMV
infection transmitted in utero. 136 Griffiths and Babbonia 76_
however reported a very low rate of transmission (17%.) This
study, however, consisted of two groups of pregnant women, those
who were seronegative at first antenatal attendance who experienced
seroconversion, and 2486 unselected women, seropositive at booking,
who were re-tested for CMV specific IgM. Thus early infections
occurring up to 16 weeks before the first antenatal attendance were
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TABLE 7.
Maternal CMV infection and relation to subsequent outcome
in children with congenital CMV.
n.Maternal n.Congenital Trimester Children
primary CMV with
infections I II III symptomatic
infections
(trimester)
Monif 134 4 4 0 2 2 2(11)
Stern 209 11 5 2 2 1 KII)
Grant 69 13 5 3 2 0
Kumar 106 14 7 0 2 5 Kill)
Griffiths 76 45 8 2 0 6 Kill)
diagnosed. In this group the rate of intrauterine transmission
was significantly lower than those experiencing a seroconversion.
161 This study suggests that first and second trimester
infections may cross the placenta less frequently than late
infections. 133
Although symptomatic congenital CMV may follow primary
infection in all three trimesters 76,106 it has been suggested
that early infections are more severe. 5,105,136 Alhfors et al. 6^
reviewed 46 cases of congenital CMV, nineteen following maternal
primary infection. First trimester maternal infection resulted in
symptomatic congenital CMV in all five children and all have
subsequent neurological handicap. However, only one of these five
cases was diagnosed in a prospective study ,and the remainder were
referred from other centres.
Stagno et al. 201 reported symptoms at birth in five of 33
infants with congenital CMV following maternal primary infection.
This was from a mixed population, some screened prospectively, and
some referred. The symptomatic infants, however, followed
infections occurring in all three trimesters.
Recurrent maternal infection was originally thought not to
give rise to symptomatic congenital infection. There have been
four case reports however, where infants have been severely
handicapped following a confirmed maternal reactivation.
3,87,173,239 In prospective studies it is difficult to classify
the type of maternal infection, as pre-pregnancy blood samples are
rarely available. The presence of CMV specific IgM in the first
antenatal blood sample suggests early primary infection, but the
absence of CMV specific IgM, particularly by some assay methods,
does not exclude primary infection (see section 3.) In the
prospective study by Alhfors 5^ 42% of maternal infections could
not be classified in either primary or recurrent groups. The use
of more sensitive and specific methods to detect CMV specific IgM
such as the RIA test has allowed more accurate definition. Stagno
et al 201 found no symptomatic infants in the 27 congenitally
infected infants following maternal reactivation compared with five
of 33 following maternal primary infection. Thus maternal
reactivation during pregnancy appears to carry a lower risk of
serious handicap in congenital CMV but the number so far followed
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up in prospective studies remains small.
10. PREVENTION AND TREATMENT OF CYTOMEGALOVIRUS INFECTIONS
CMV is usually a benign infection in healthy children and
adults. Prevention or treatment of infections is important only for
those groups who are susceptible to symptomatic infection, such as
low birth-weight neonates, immuno-suppressed individuals, and
infants in utero. The acquisition of CMV from blood transfusion
has been prevented by restricting blood products given to
seronegative subjects, to products from CMV seronegative donors.
This has nearly eliminated severe acquired CMV infections in
neonatal intensive care units. 14,104,240 The matching of renal
transplant recipients by CMV status, with the donor organ, has
reduced, though not eliminated, CMV as a serious opportunist
organism in the post-operative immuno-suppressed period. lfj
The multiple sources of CMV to which a pregnant woman may be
exposed makes it difficult to prevent the acquisition of primary
CMV in pregnancy. Indeed, there is little evidence that
professionals exposed to known sources are at greater risk than the
population as a whole 2,47 and attempts to reduce exposure of
nurses to known cases of CMV has been found to be impractical and
unnecessary. 244
Passive Immunisation
Immunoglobulin has been used in the immuno-suppressed to alter
the natural history of CMV infection. In a study of bone marrow
transplant patients, Winston et al 233 were not able to prevent
the acquisition of CMV by the administration of 5% immunoglobulin
solution. Symptomatic infections and pneumonia appeared to be
reduced in the treated group. High titre CMV specific
immunoglobulin may, however, have a greater role to play. Condie
et al 29^ completely prevented the acquisition of CMV by bone
marrow transplant recipients with repeated administration of high
titre specific immunoglobulin in the first 120 days after
transplantation. They found no protection if non-specific
immunoglobulin was given. This benefit could not be maintained,
however, if granulocyte transfusion were given from CMV positive
donors, demonstrating that immunoglobulin has no effect if the
organism is protected by donor cells during acquisition. 129
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High titre CMV specific globulin has also been used to modify
symptomatic CMV infections in renal transplant patients 141 and,
in one case report, presumed blood transfusion acquired infection
in a premature infant. 186 The scarcity of CMV specific
immunoglobulin makes it unlikely that this form of treatment has
any role in prevention of congenital infection.
Vaccination
A successful live attenuated vaccine has been developed for
murine CMV 135 The first attempts to develop a vaccine for human
CMV was by Elek and Stern. 48 They used strain AD 169 and
subjected it to 56 passages to attenuate the virulent virus. The
"vaccine virus" was then administered to 26 volunteers and 25
subsequently had a rise in CMV antibodies. The antibody produced
showed cross-reactivity to not only AD 169 strain , but to several
other wild and laboratory strains. No live virus was isolated
from urine or throat swab, suggesting that the vaccine virus had
not established latency. 140
Plotkin et al 156 similarly subjected the Towne strain to 129
passages to produce a vaccine. This vaccine virus strain
stimulated humeral immunity when given subcutaneously but not
intranasally. CMV specific cell mediated immunity was also
transiently stimulated. This vaccine has now been extensively
tested in renal transplant subjects. 63,158 It has not been
shown to prevent the acquisition of CMV but it may modify the
severity of complications such as pneumonitis. The vaccine
strain, however, has been shown to be safe and not to cause latent
excretion itself despite immunosuppression in all the subjects.
The vaccine has not been tested on pregnant subjects, though it has
been given to paediatric nurses. 54 This resulted in a similar
antigenic response but the numbers were too small to demonstrate
the efficacy of preventing the acquisition of wild infection and
there is no data on the availability of the vaccine to prevent
congenital infection.
Antiviral Drugs
Cytosine arabinoside has been used in children with
symptomatic congenital CMV infection. 126 In large doses, viral
excretion was temporarily suppressed, but there was no symptomatic
change in the infants. All had, by definition, severe disease,
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and doses which suppressed virus excretion were too toxic for
long-term use.
Adenine arabinoside, which is used in the treatment of severe
herpes simplex infections, is not effective against human CMV. It
has a similarly suppressive effect on CMV excretion but little
clinical benefit 26 although occasional cases have improved. 35^
Severe toxicity has been noted in renal transplant patients. 120
Acyclovir, which is highly effective against herpes simplex
virus, is much less active against CMV. 218 The drug requires
intracel1ular activation with the enzyme thymidine kinase. Most
herpes group viruses stimulate the production of this enzyme in
infected cells, but not human CMV. 177 The drug is effective in
preventing death from murine CMV in immunodeficient mice 23^ but it
has a much less marked effect in human infections. Plotkin et al
157 have demonstrated that in large concentrations the drug
inhibits CMV replication by 90% in vitro but had great difficulty
in achieving similar serum concentrations in four infants with
congenital CMV infection. Doses of 15 mg/kg produced temporary
reduction in viruria but no clinical effect. Yeagar et al 241
only achieved "therapeutic" levels in one of four infants with CMV.
This child improved but had also been given CMV specific
immunoglobulin. The other three infants showed no clinical
improvement. Acyclovir may therefore eventually prove to be a
useful drug if high doses can be used, and new analogues may be





Cytomegalovirus infection is the commonest known congenital
infection. The prevalence of maternal infection and the incidence
of congenital CMV vary widely throughout the world. While the
majority of congenitally infected infants are asymptomatic at
birth, a proportion develop significant handicaps in later life.
As yet, there is no method of prevention or treatment of infection
available to pregnant women or their infants, and no agreed policy
on management of CMV in pregnancy. It was, therefore, necessary to
conduct a prospective study to assess the risk of acquisition of
CMV in pregnancy, the rate of intrauterine infection and the
prevalence of congenital CMV on a British population, to assess the
extent of the morbidity resulting from CMV in pregnancy. The aim
ultimately was to establish whether congenital CMV infection was a
sufficiently serious public health problem to justify attempts at
prevention by vaccination. This thesis reports the findings of
the follow-up of children with congenital CMV, up to three years of
age, identified between 1.3.80 and 30.6.83, and assesses the impact
of congenital CMV on this population.
1. POPULATION SCREENED
(i) As part of a study of the epidemiology of CMV infection in
pregnancy, all women attending three maternity units in London were
screened for evidence of previous CMV infection. At their first
antenatal visit, a questionnaire was completed. Details of age,
parity, marital status, race, country of birth, maternal and
partner's occupation were obtained at interview by the midwife
(Appendix 1). A blood sample collected at this visit was tested
by complement fixation (CF) test, for the presence of CMV specific
antibodies. 172 If this sample was positive ( a titre of >1:10)
no further samples were requested and the sample stored for further
analysis if required. Those women seronegative for CMV antibody
were retested at intervals to detect primary CMV infection
(seroconversion).
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As soon as possible after birth a throat swab was collected from
all infants born at the three hospitals and cultured for CMV to
detect congenital CMV infection. A short form was completed by
the midwife providing details of date of birth, birthweight, sex,
gestation and any obvious malformation (Appendix 2). This form
was returned to the laboratory with the throat swab. The
information from the antenatal questionnaire, infant details and
laboratory results of maternal serology and swab culture were all
coded onto a single form (Appendix 3).
(ii) Diagnosis of congenital CMV infection
The throat swabs were collected into virus transport medium,
within the first few days of life, and kept at $ C prior to
transport to the laboratory. Throat swab was chosen for screening
as it has been shown to be effective 127 and is more appropriate
for large-scale screening than the collection of urine samples.
However, since no single method is 100% sensitive, urine and cord
blood samples were also collected from those infants most at risk,
that is, infants of mothers who experienced primary infection in
pregnancy. In addition, cord blood samples were obtained from all
babies born at one hospital and retained for testing when
congenital infection was suspected.
In the laboratory, throat swabs were inoculated, in duplicate,
into tubes containing tissue culture of human embryo lung cells,
incubated at 4(f C, and inspected at regular intervals for four
weeks. CMV was identified by the appearance of typical cytopathic
effect (CPE). Urine samples were first filtered and then
inoculated direct into cell culture, in duplicate, as for throat
swabs.
Cord blood samples were separated and the serum tested
initially by CF test to confirm the presence of CMV IgG antibodies.
If positive, the samples were further tested by Dr. P.D. Griffiths
for CMV specific IgM antibodies by solid phase radioimmunoassay. •
75
A diagnosis of congenital infection was made when virus was
isolated from either the throat swab or urine sample within three
weeks of birth. 166 In addition, any infant with CMV specific
IgM antibodies in cord blood in titre >1:100 was included as a
case. 75 Infants transferred from other neonatal units were not
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included in the study.
(iii) Definition of type of maternal infection
Congenital CMV may follow either primary maternal infection or
recurrent infection. 194 Primary infection was diagnosed when
CMV antibodies were acquired during pregnancy, and recurrent
infection when CMV specific antibodies were present prior to
pregnancy. However, the detection of antibodies at the first
antenatal attendance does not exclude primary infection occuring
between conception and this visit. As CMV specific IgM
antibodies detected by RIA are consistently associated with recent
primary infection and persist for up to 16 weeks, it is possible to
distinguish primary from recurrent infection in seropositive women
when they presented for antenatal care prior to the 16th week of
pregnancy. 74,97,98
In the present study, the type of maternal infection was,
therefore, classified as follows:
I Confirmed primary infection :seroconversion during pregnancy
II Presumed primary infection :CMV IgG and specific IgM anti¬
body present in first antenatal
serum sample
III Confirmed recurrent infection:CMV specific antibody present
prior to pregnancy
IV Presumed recurrent infection :CMV IgG antibody present, but
CMV specific IgM absent prior
to the 16th week of pregnancy
V Unciassifiable :CMV IgG antibody present, IgM
absent at first antenatal
attendance after the first 16
weeks of pregnancy
2. LONGITUDINAL STUDY OF THE CHILDREN WITH CONGENITAL CMV
INFECTION
In this study all children who were diagnosed to have
congenital CMV infection were followed up. As virus isolation may
take up to three weeks, the diagnosis was often not made until the
child was several weeks old and had been discharged from hospital.
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Once the diagnosis was confirmed, the research paediatrician (PMP)
contacted the consultant obstetrician and paediatrician and
informed the general practitioner. With their consent,
arrangements were then made to visit the family.
i) Initial visit and examination
Once the parents had been told the diagnosis and had consented
to take part, details of paternal age, race and country of birth
were collected together with details of the previous and family
health of both parents (Appx 4). Particular enquiry was made into
a family history of deafness and/or psychomotor delay. Opportunity
was also taken to clarify any details on the Maternal Master Card
which were ambiguous, particularly parental occupation. The
mother was also asked further details of her pregnancy and in
particular if she smoked or suffered from pre-eclampsia, antepartum
haemorrhage or gestational diabetes melitis. She was also asked
for details of labour and delivery, and about the progress of her
infant in the neonatal period. These details were later confirmed
by reference to hospital records.
Each infant was examined personally with measurement of
occipitofrontal circumference (OFC) followed by a complete physical
examination to detect eye defects, cataract, cardiovascular
anomalies, rash, respiratory infection, abdominal masses, and, in
particular, hepatosplenomegaly. Examination of the central
nervous system included observation of the state of awareness,
light reflex, ability to fix and follow, the presence of rooting,
grasp and Moro reflexes, and symmetry of tone and movement.
Finally, a urine sample was collected from each
infant to monitor virus excretion.
ii) Review of maternal and neonatal records
The case records of all mothers and their babies were
scrutinised to confirm infant gestation, problems during pregnancy,
mode of delivery and, in particular, the reason for intervention if
required. Measurements of birth weight, length, OFC, placental
weight and Apgar scores were recorded, together with details of
type and length of neonatal resuscitation and other neonatal
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problems. In jaundiced infants, the maximum serum bilirubin
measurement was recorded, and any treatment received. Any
abnormality noted was recorded and the diagnosis on discharge was
based on the paediatrician's assessment.
3.SELECTION OF CONTROLS
Since none of the features of congenital CMV are sufficiently
specific to be synonymous with infection it was necessary to
compare the progress of congenitally infected infants with a group
of control children. As many of the problems which may result
from CMV may be influenced by such variables as maternal race, age,
parity, marital status, social class and infant sex, controls were
matched for these factors. Controls were selected from within the
study population, once congenital infection had been excluded,
using the Maternal Master Cards completed at the antenatal clinic.
The matching criteria were: maternal age within two years, parity
(primagravidae or multigravidae,) marital status (married and
cohabiting women were regarded as synonymous and single women
whether unmarried, widowed, separated or divorced as single), race
and country of birth. No information was available on paternal
race at the time of control selection, so no attempt was made to
match children of mixed race except by maternal race. Social
class was matched on paternal occupation using the Registrar
General's classification. 165 For single mothers who were not
cohabiting their own social class was used for matching. If several
possible controls were available who meet the criteria, other minor
factors such as family size, country of birth and maternal
occupation, and date of birth of the baby were used to obtain as
closely matched controls as possible. No attempt was made to
match for infant birthweight or gestation as these were factors
which may be influenced by CMV.
Once selected, the mothers of control children were contacted
after the general practitioner's permission had been sought. If
agreeable, they were visited personally, at home, and told of the
study procedure and invited to take part. Once permission was
given, they were interviewed in exactly the same way as the parents
of congenitally infected infants and the infants examined in an
identical manner. The hospital records were also used to complete
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the data. Following this initial visit which took place usually
when the controls were about three months old the follow-up of both
congenitally infected children and controls was identical. Since
both parents were fully informed of the study it was not possible
to examine the children blind.
4. SUBSEQUENT EXAMINATIONS
The initial assessment of cases was carried out at about six
weeks of age. The children were then seen in the paediatric
outpatient clinic at three, nine, 18, 24, and 36 months. As the
control children were not seen until three months, the initial
examination and three-month visit were combined. Any child who
did not attend was seen at home, if possible, including those who
moved out of London.
At each visit the parents were asked for an assessment of the
child's general health since, the last visit, and specific enquiry
was made into the frequency of upper and lower respiratory and ear
infections. This was assessed using the parents' judgment: i.e.
no infections, occasional infections and frequent infections. The
severity of infections was assessed by the type of treatment
required ranging from symptomatic measures at home to admission to
hospital.
Enquiry was also made into the parents' opinion of the child's
hearing and vision and the progress in development since the last
visit. This was followed by a developmental assessment and
completed by a general physical examination including measurements
of height, weight and OFC. A urine sample was collected from each




Since each child was seen at least five times in the first
three years a method of developmental assessment was required which
would be simple to perform and reproducible at different ages. As
a physical examination and hearing assessment were also required,
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the developmental assessment needed to be short and not involve the
use of complex equipment. The Stycar sequences provided a
descriptive analysis of the abilities of children up to five years.
181 This formed the basis of a method of assessment used in the
National Childhood Encephalopathy study. 134 With the help of the
late Dr. Sheridan the authors selected 151 cardinal items to cover
the ages up to 36 months._13 These items were divided into four
major areas of development and scored to produce a numerical
measure of the child's developmental level which could be compared
with chronological age (Appx 5). This method of assessment was
particularly appropriate for the present study, since it not only
met all the conditions above, but also allowed comparison
longitudinally and with other methods of assessment. There was no
need to use external standardisation as the results would only be
used to compare cases with controls.
i i) Griffiths Assessment
At two years a full measure of the child's developmental
progress was obtained using the Ruth Griffiths developmental
quotient. This has been well standardised on preschool
British children and correlates well with subsequent measures of
intel1igence.
iii ) Stott Test of Motor Impairment
Items from the Stott test 209 were used to assess fine motor
coordination at the 36 month visit. This was combined with the
"Draw a Man test" 65 as an adjunct to the Stycar sequences.
Children at this age respond poorly to timed tests, so a simple
score system was used to judge the proficiency in each task. The
"Draw a Man" score depended on the number of additions such as
arms, legs and fingers added to a recognisable head. The tests
and scoring system used are shown in Appendix 6
6. AUDIOLOGICAL ASSESSMENT
Each child received a full audiological assessment before the
first birthday, and again at three years, to detect deterioration.
Both these audiological assessments were carried out by a
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paediatric audiologist.
The nine month assessment was done by distraction tests to
voice and high and low tones. A tympanogram was used to assess
middle ear function. At the three year visit, conditioning tests
were used to voice and pure tones. If the child was cooperative
these were repeated with headphones to produce a full audiogram.
A Kendal toy test was also used to assess speech sound
discrimination. The impedance tympanogram was repeated at this
visit.
Any child who failed at these screening tests was seen
subsequently to monitor the hearing levels. This allowed
transient problems to be excluded and permanent neurological
abnormalities to be monitored for any deterioration of hearing
levels.
7. ASSESSMENT OF GROWTH
The growth of children with congenital CMV and controls was
compared using population studies of normal children to provide
normative data. Birth weights were compared with the data
prepared by Thompson et al corrected for gestational age, sex and
birth order. 217 Data from Usher and McClean on the length and
head circumference, by gestation was used for comparison as
equivalent data on a uniform British population is not available.
221
Standards of longitudinal growth in boys and girls were
obtained for height from Tanner, Whitehouse and Takashi 215 and
for head circumference from Tanner and Thomson. 214 All
measurements were then converted to standard deviation scores so
that they were directly comparable.
The standard deviation score (SDS) is a measure of the number
of standard deviations the measurement is from the expected mean at
each age. In a normal poulation, therefore, the mean SDS will be
zero. SDS is calculated according to the formula (x - x)SD where
x is the measurement, x the mean (ie. 50th percentile for that age)
and SD the standard deviation at that age. All calculations of
age at the time of measurement were corrected for prematurity.
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8. MATERNAL CHARACTERISTICS ASSOCIATED WITH AN INCREASED RISK OF
CONGENITAL INFECTION
The maternal, racial and socioeconomic backgrounds of children
with congenital CMV were compared with the population screened to
ascertain whether congenital CMV was more prevalent in a particular
subsection of the study population. The data of maternal
characteristics is not yet complete for the full period of infant
screening. The available data consisted of 6912 women who had
delivered live births at Hospitals I and II over a two year period
and a consecutive group of 1000 women who had live births at
Hospital III. Infant screening took place between 1.3.80 and
30.6.83, for a period of 2.4 years at Hospital I, 3.3 years at
Hospital II, and 3.25 years at Hospital III. Since the women
attending each of the three hospitals were significantly different
in terms of race and social background, the data cannot be combined
without adjustment for the proportion of women attending each
hospital, the different periods of maternal data available and
differing periods of infant screening.
The data therefore were used to construct an estimated
population similar to the actual population screened. Assumption
was made that maternal characteristics of women attending each
hospital remained constant throughout the screening period. The
maternal data from each hospital was multiplied by the ratio of the
period of infant screening to the period of available maternal
data. The data from each hospital was then combined to form the
"estimated population" reflecting the characteristics of the actual
population screened, and directly comparable with the mothers of
infants with congenital CMV.
The congenitally infected infants and the population data were
modelled by group logistic regression using the GLIM statistical
system in order to estimate prevalence rates and test for
differences in prevalences between groups. VI
9. FAMILY STUDIES OF CHILDREN WITH CONGENITAL CMV
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In order to determine whether infants with congenital or early
acquired CMV were an important source of infection for their
families, eight families were selected for more detailed study.
In each family, samples of serum were collected from all adult
members and tested for the presence of CMV antibody by CF test.
172 The seropositive samples were retested by RIA for CMV
specific IgM to detect recent primary infection. _74 Thereafter
each seronegative member of the family was retested at intervals to
detect seroconversion. Urine and throat swab samples were
collected from those members of the family who were seropositive
and children in whom serological tests were felt to be
unjustifiable. If virus was recovered from any contact the
restrictive endonuclease typing was carried out of all virus
isolates from that family to compare DNA structures and detect
related strains. 56
10.ANALYSIS OF RESULTS.
The clinical, audiological and laboratory results were coded
and stored using the computer facilities provided by the University
of London central computer. Results were analysed using standard
statistical tests available on the SPSS program. The complex
multifactorial analyses of growth, developmental assessment, and





1. THE IDENTIFICATION OF CHILDREN WITH CONGENITAL CMV INFECTION
The screening of infants for congenital CMV infection took
place between 1.3.80 and 30.6.83, and fifty infants were diagnosed.
Overall 90% of infants were screened, the rates for each hospital
being 93.5%, 90.5% and 83% respectively. The rate of screening
was similar in low birth weight and premature infants and infants
of normal birth weight.
The methods of diagnosis are tabulated in table 8. The
throat swab was positive in 42 of 48 cases (87.5%) and was the sole
method of diagnosis in 18 cases. In the remaining 30 cases cord
blood samples and/or urine samples were also available to confirm
the diagnosis. In one case the initial urine sample was negative
for CMV when the throat swab was positive, but further samples of
urine contained virus. In total, 24 of 25 (96%) urine samples were
positive by virus culture. Cord blood samples were available in
19 cases. When tested for CMV specific IgM by RIA, 16 (84%) had a
titre >1:100 but in three cases the titre was <1:50 and this was
regarded as negative, although virus was isolated from throat swab
and/or urine.
In two cases throat swabs were not collected, but urine and
cord blood samples were available, and both were positive.
In summary, therefore, urine culture was most sensitive as a
method of diagnosis with a false negative rate of 4%, while throat
swab culture and cord blood IgM assay have false negative rates of
12.5% and 16% respectively.
2. TYPE AND TIMING OF MATERNAL CMV INFECTIONS
Table 9. shows the type of maternal CMV infection and when it
occurred. The mothers of 18 congenitally infected children
seroconverted during their pregnancy and the mothers of 29 were
seropositive at their first antenatal attendance. No serological
data was available in three cases.
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TABLE 8.
Method of diagnosis of 50 children with congenital CMV infection.
Samples collected n. CMV Isolated(%) CMV Specific
T.S. Urine IgM >1:100
T.S. + Urine + IgM 10 8 10 7
T.S. + Urine 13 13 12
T.S. + IgM 7 3 - 7
T.S.only 18 18 -
Urine + IgM 2-2 2
Total 48 25 19 50 42(87) 24(96) 16(84)
T.S. = Throat swab
TABLE 9.
Type and timing of maternal infection in 50 cases of congenital
CMV






















Total 50(100) 97 14 20
When the 29 initially seropositive samples were further tested
for the presence of CMV specific IgM, 14 were positive and presumed
to follow recent primary infections. No specific IgM was present
in the remaining 15 cases. In three of these, sera from a
previous pregnancy was available and found to be positive for CMV
antibody, confirming that recurrent infection had occurred and was
transmitted in utero. In the seven cases who booked within 16
weeks of their last menstrual period, the absence of CMV specific
IgM excluded recent primary infection, and maternal infection was
presumed to be recurrent. In the remaining five cases who booked
for antenatal care after 16 weeks no specific IgM was detected, but
early primary infection in pregnancy could not be excluded and the
type of maternal infection could not be defined.
In all but two of 32, primary maternal infections (both
confirmed and presumed) it was possible to assess the trimester in
which infection had occurred, from the dates of seroconversion and
the persistence of CMV specific IgM. In the two cases for which
this was not possible, the first antenatal blood sample was
seronegative at 9 and 15 weeks respectively, and cord blood was
positive, confirming seroconversion but no follow-up maternal serum
sample was available to test for CMV specific IgM. Nine (28%) of
primary infections occurred before 16 weeks, seven (21%) between 16
and 27 weeks and 14 (43%) at 28 weeks or after.
3. SELECTION OF CONTROL CHILDREN.
Two control children were selected for each case. Suitable
controls were selected for all but two cases. The two children
for whom no controls were selected live permanently abroad and it
was thought inappropriate to attempt to select controls. Further
analysis of the two groups (Table 10.) showed no significant
differences on the matched criteria of maternal age, race, country
of origin, marital status, family size, social class and infant
sex. Although it was not possible to match for paternal race and




Comparison between children with congenital CMV and control
children
Maternal characteristics Congenital CMV Controls
n.=50 n. =97
Age(years) mean(SD) 24.06(5.8) 24. 13(5.8)
Parity me an(S D) 0.54(1.1) 0. 48(1.0)
Marital status Single 23 40
Married 24 51
Cohabiting 3 6
Social class: Non-manual 13 (23) 32 (56)
Paternal(House) Manual 9 (11) 22 (26)
Other 5 (16) 3 (16)
Single parent 23 40
Race Caucasian 32 63
As i an 4 8
B1 ack 14 26
Infant characteristics.
Sex Male 26 52
Female 24 45
Race Caucasian 29 56
Asi an 3 8
Black 13 26
Mi xed 5 7
*Social class - Other = H.M.Forces,students,not known.
(House) = Social class of householder including
single parents.
SD = Standard deviation.
4. CHILDREN WITH CONGENITAL CMV.
i) Prenatal problems and fetal growth
There was no difference in the frequency of hypertension,
pre-eclampsia, antepartum haemorrhage or gestational diabetes
during pregnancy in mothers of congenital infected infants and
controls. The proportion of smokers was similar. The rate of
premature delivery was the same in cases and controls, and there
was no difference in type of delivery. None of the mothers of
congenitally infected infants reported symptoms suggestive of CMV
infection. Travel abroad was significantly more frequent (P<0.02)
though most stayed within Europe (Table 11.).
The mean gestational age, birth weight and length of
congenitally infected infants were not significantly different for
controls (Table 12). The mean head circumference of congenitally
infected infants was slightly lower than in controls with greater
variance, but this was not significant. When account was taken of
gestation, intrauterine growth retardation and microcephaly
(0FC<3rd percentile) were no more frequent in cases compared with
controls.
ii) Problems noted in the neonatal period (Table 13.).
One child with congenital infection was noted to have a major
congenital abnormality (ventricular septal defect). One control
child had a similar abnormality. Two other controls had
abnormalities, one unilateral ptosis, the other an accessory digit.
There was no evidence of increased fetal hypoxia in congenitally
infected infants as judged by the Apgar score, or number admitted
to SCBU than controls. The frequency of jaundice and maximum
bilirubin level were similar and hepatomegaly was noted in only one
infant with congenital CMV.
Two children presented as suspected cases of intrauterine
infection and both had CNS symptoms. The first suffered from
severe intrauterine growth retardation, severe microcephaly,and
dystonia. The second child had hepatomegaly, hypotonia and
stridor, and required tube feeding. A third child, in whom
congenital infection was not clinically suspected, developed
respiratory distress on the third day due to pneumonitis,
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TABLE 11.
Maternal factors in children with congenital CMV and controls.
CMV n.50 Controls n.97 p Value
Smokers 12 12 NS
Hypertension 2 14 NS
Antepartum haemorrhage 1 1 NS
Gestational diabetes 1 3 NS
Travel abroad 8 5 p<0.02
Assisted delivery 16 21 NS
NS = Not significant.
TABLE 12.
Intrauterine growth of children with congenital CMV and controls.
CMV n.50 Controls n.97 p Value
Mean (SD) Mean (SD)
Birth weight (kgs) 3.21(0.68) 3.22(0.48) 0.93
O.F.C. (cms.) 33.8 (2.2) 34.3 (1.5) 0.12
Birth length (cms.) 51.6 (4.8) 51.75(3.1) 0.78
Gestation (weeks) 39.3 (1.8) 39.3 (1.6) 0.83
n.Small for gestational 5 3 0.09
age.
n.0.F.C.<3rd percentile 11 11 0.1>p>0.05
O.F.C. = Occipitofrontal circumference
TABLE 13.
Features noted in the neonatal period in children with congenital
CMV and controls.
n.Admitted to S.C.B.U.
Mean Apgar 5 mins

















*,+ = Two children with multiple problems.
associated with a small VSD,and in addition had the characteristic
appearances of fetal alcohol syndrome. Recovery was also
complicated by necrotising enterocolitis. The respiratory illness
was likely to be due to CMV, as no other pathogen was isolated, the
chest X-ray appearances showed bilateral infiltrates and there was
no response to antibiotic therapy. Two other cases had
respiratory problems, one noted above with stridor related to
hypotonia, and another with transient tachypnoea of the newborn.
A wide range of other problems occurred in cases and controls.
Two infants with congenital CMV suffered from localised Candida
infections and one had conjunctivitis. One control child was
admitted to SCBU for treatment of hypothermia, two developed
jaundice; one due to glucose-6-phosphate dehydrogenase deficiency,
the other ABO incompatibility and one suffered from positional
talipes.
In summary only three (6%) cases had significant symptoms in
the neonatal period. No child had splenomegaly, rash or
thrombocytopaenia.
5. FOLLOW-UP OF CHILDREN WITH CONGENITAL CMV AND CONTROLS
All but one of the 50 cases has been followed up personally,
and, for the remaining child, who lives abroad, several reports are
available from the child's personal physician. To date, (1.6.84,)
none of the cases or controls have died and none of the cases have
withdrawn from the study. Seven controls have withdrawn from the
study at ages ranging from 5-32 months. However, all but two
completed the 9-month assessment, and one completed the two-year
assessment. The number of children seen at each age is summarised
in Table 14.
Initial examination
The initial assessment provided an opportunity to confirm the
abnormalities noted at birth and to examine the child in detail to
identify previously unrecognised or new abnormalities. The number
of children with abnormalities is noted in Table 15, with a list of
new abnormalities noted at each assessment. There was a wide
range of abnormalities in both the children with CMV and controls.
Two distinct problems were particularly apparent in children with
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TABLE 14.
Follow-up of children with congenital CMV and controls,
number examined at each age.
Age (months) 3 9 18 24 36
CMV n.50 49 47 30 29 18
Controls n.97 97 90 65 54 34
TABLE 15.
Children with CMV and controls; abnormalities noted at each
examination.
Congenital CMV Controls
Age(mths.) n.abN/ New n.abN/ New








































G6PD Def :G1ucose-6-phosphate dehydrogenase deficiency.
CMV in the first four months, ie. hepatosplenomegaly and
interstitial pneumonitis.
Hepatosplenomegaly
Only one child had hepatomegaly in the neonatal period.
However, two further children developed hepatomegaly in association
with splenomegaly after the neonatal period. One of these
children had had pneumonitis as a neonate, but, at the age of three
months, when the respiratory problem was improving, transient
hepatosplenomegaly was noted. The second child was admitted to
hospital at four months with the acute onset of a rash described as
"erythema multiforme" associated with hepatosplenomegaly. The
rash subsided quickly but asymptomatic hepatosplenomegaly persisted
until the age of 18 months with no recurrence of the rash.
Interestingly, one control infant had a non-specific illness
at the age of 9 months characterised by generalised lymphadenopathy
and hepatosplenomegaly. Infectious mononucleosis due to CMV and
EB virus were excluded and resolution took place spontaneously over
one month.
Respiratory Complications.
Six congenitally infected infants presented with respiratory
symptoms, five at or before three months and one at four months.
All were characterised by tachypnoea, hyperinflation and
non-specific changes on chest X-ray. None was severely ill and
only one required hospital admission. In all six instances CMV
was cultured from pharyngeal aspirate as well as urine samples
during the acute phase of the illness. Bacterial culture, viral
culture for adenovirus, RSV, influenza and parainfluenza and
serological titres for mycoplasma were all negative. In one child
C.trachomatis was also isolated. The acute illness lasted from
one week to one month in duration and the pharyngeal aspirate
became negative, for CMV culture, with resolution of symptoms in
all cases despite continued excretion of virus in the urine. Two
children have continued to have intermittent respiratory problems
up to one year of age.
The pattern of illness and the absence, except in one case, of
an alternative pathogen, suggests that CMV was acting in these six
children as a primary pathogen. The frequency of respiratory
disease in congenitally infected infants was highly significant
(p=0.0001).
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One further case had a respiratory illness suggestive of
B.Pertussis infection. Unfortunately previous antibiotic therapy
did not permit bacterial isolation but pharyngeal aspirate was
negative on CMV culture. One control child has had a number of
episodes of "bronchitis" treated by her general practitioner but
was not investigated.
Nine-month Assessment and Hearing Tests
Major delay in psychomotor development and neurological
abnormality were apparent in two children with CMV at the
nine-month assessment. Both had spastic quadriplegia. In one of
these neurological abnormalities were suspected at birth and
spastic quadriplegia and severe mental retardation with severe
microcephaly confirmed in the first six months of life. She also
has frequent fits and bilateral optic atrophy. Electrocochleo-
graphy confirmed normal hearing.
The second child was SFGA (Bwt 2.0 kg OFC 28 cm) but otherwise
normal at birth. Initial developmental progress appeared normal
but he was not sitting by nine months and manipulation was
immature. Physical examination revealed mild spastic
quadriplegia. Fundoscopy was normal and skull X-ray revealed no
evidence of intracranial calcification. He also now has frequent
fits.
Hearing Assessments
Full hearing assessments have been carried out on 47 cases and
88 controls. In addition, the two cases who live abroad have been
tested by their personal paediatricians; one has conductive hearing
loss and the other has normal hearing. The parents of one
congenitally infected child refused to attend for hearing
assessment, but there is no clinical suspicion of deafness. Among
the controls, six have withdrawn from the study, and three were
unable to attend for hearing assessments. These children were
seen at home and clinically hearing was normal. The results of
the hearing assessments are shown in Table 16. Five cases (11%)
have sensorineural deafness, three (6.5%) are bilateral and hearing
aids have been prescribed. In two of these, there was also a
conductive element. In one case with bilateral sensorineural
deafness, neurological examination including fundoscopy was normal,
despite the presence of symptoms in the neonatal period
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TABLE 16.
Hearing assessments in children with congenital CMV and controls.
Congenital CMV Controls
n.50 n.97
Age (months) 9 36 9 36
n.tested 47 14 88 33
Normal 27 14 55 26
Sensorineural Bilateral: 1 _
Deafness(SN)
Unilateral: 2 - - -
Mixed (SN + CD) Bilateral: 2 - - -
Conductive Bilateral: 15 _ 21 4
Deafness(CD)
Unilateral: - - 6 3
Equivocal - - 6 -
(hepatomegaly and hypotonia). In a second child, spastic
quadriplegia is also present. In this child subsequent testing
revealed resolution of the conductive element but despite this the
hearing thresholds deteriorated to 90 dB bilaterally between nine
and 18 months. It has not been possible in the two children with
suspected unilateral deafness to perform full audiometric testing
with masking, using earphones, but this will be done at the four
year examination to ascertain the true thresholds more accurately.
Sensorineural deafness was not present in any of the controls.
Conductive hearing loss was common in both cases and controls.
At the nine-month examination 17 cases (37%) had bilateral
conductive loss (including two mixed) compared with 27 controls
(31%), 21 bilateral and six unilateral, conductive loss. This
difference was not significant (x*= 0.246). To date 13 cases and
21 controls have been retested. This has confirmed bilateral
sensorineural deafness in all three cases, conductive deafness in
five, a further five with previous conductive deafness have
resolved and five await retesting. Amongst controls conductive
deafness has persisted in nine and has resolved in 11 whereas seven
await retesting.
Further Hearing Assessments at 36 Months
Only one child showed a deterioration in hearing levels after
the first hearing assessment. This child has not yet reached 36
months but repeated tests show a stabilisation of hearing
thresholds from 18 months. None of 14 cases and seven of 33
controls had persistent conductive hearing loss at 36 months. Not
all children are sufficiently mature at 36 months for headphone
audiometry so further cases of unilateral deafness cannot be
excluded. However, no sensorineural deafness has been detected
since the first audiological assessment.
18 Month Assessment
Few new problems became apparent after one year of age (table
15). One child, who had pneumonitis, continues to have episodes
of wheezy bronchitis. Delay in psychomotor development became
apparent, for the first time, in two older children. One child,
with congenital CMV, already identified at risk due to fetal
alcohol syndrome, continues to thrive poorly with height, weight
and OFC all below the third percentile. This child has mild
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psychomotor delay despite normal neurological examination. It is
possible that fetal alcohol syndrome may account for this child's
problems and CMV may be an incidental finding. The other, a control
infant, with an OFC above the 97th percentile, also has mild
psychomotor delay and particularly poor language development.
Assessment at 36 Months
No further abnormalities of physical or intellectual
development have been detected in those children who have reached
36 months and there has been no evidence of progressive disease
amongst the cases (table 15).
6.MEASUREMENTS OF INTELLECTUAL PROGRESS IN CHILDREN WITH CMV
COMPARED WITH CONTROLS.
Griffiths assessment at 24 months
To date the developmental quotient (DQ) of 29 cases and 53
controls have been measured. Intellectual impairment was defined
as a DQ more than 2SDs below the mean score of control children.
Four cases and two controls fell into this category and this
difference was not significant (P=0.09 Fisher's exact test.)
The mean score of cases and controls for both overall DQ and
the five subscores are shown in Table 17. While the scores for
cases are lower than for controls this is not significant (P=0.08).
All children in the study, both with congenital CMV and
controls,were further divided up to exclude those with permanent
neurological sequelae on follow-up. All five children with
neurological sequelae were congenitally infected and included the
two children with spastic quadriplegia, one with bilateral and two
with unilateral sensorineural deafness. Comparison between
controls and congenitally infected infants, with no sequelae,shows
no evidence of an effect of CMV on intellect at two years in the
absence of neurological abnormality. The subscores show no
specific area of development has been affected. These data were
subjected to logistic regression analysis to separate the effects
of CMV from the effect of social class and other matching
variables. The independent effect of each variable, on an
individual child's DQ score, compared with controls, is shown in
Table 18. This confirms that there was no difference in
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TABLE17.
MeanDevelopme talQu ti tfchildrenw thc ng italCMVandco rols(SD)
Controlsn.53MV294V.5 Nosequelaeeurol gicalsequel e
Total101.8(8.3)95.02 .7)210 169(40.1)p0 Locomotor106.3(8.3)1 423. )14 278 0(42.6)p01 Hearing98.6(14 5)1 825 14759(32. )p0.001 andspeech Eye-hand97.2(.5)0 523 )10 462.(39.9)p0 01 coordination Social106.4(13.3)02 65 9874(42 1)p0. 0 Performance99.5(.4)6 424 2)102.21 . )70 0(45.4)p005 p;significancelevelCMVneurologicalsequelacomp redwithontro s.
TABLE 18.


















































Comparison assumes DQ = 100 for female controls of mothers <20
yrs, non-manual social class, white race, para 0, single marital
status.
C.I. Confidence interval
performance of children with uncomplicated CMV compared with
controls. It also highlights the significant effect of social
class irrespective of the presence of congenital infection and the
lesser effects of race and increasing family size on developmental
achievements.
Children with neurological sequelae, as defined above, have a
significantly lower mean DQ compared to controls both in total
score and in subscores (Table 17) suggesting either that these
children suffer also from intellectual impairment or their motor
and sensory disabilities interfere with their ability to perform
the test. The two most severely affected children, both with
spastic quadriplegia, performed very poorly. Two children with
deafness (one bilateral and one unilateral) had normal overall
scores, but both had reduced hearing and speech scores (84 and 88
respectively.) Logistic regression (fig.2) confirms that the poor
performance in this group was due to the presence of congenital CMV
and not due to associated factors such as social class as there
were no interactions between variables in the regression analysis
(P >0.2)
In the children who had intellectual impairment (ie. DQ > 2 SD
below mean of controls) three cases came from the neurological
sequelae group. The other congenitally affected child had fetal
alcohol syndrome but no specific neurological deficit. One of the
control children in this group was noted to have macrocephaly and
may, on further detailed assessment by a speech therapist, have a
specific language disorder. The other control who performed
poorly had severe behaviour problems and associated language delay.
Stott Test of Motor Coordination
To assess the abilities of the children in fine motor
manipulation, items from the Stott test of motor impairment were
used, with the "Draw a Man" test, to identify children with "soft"
neurological defects, such as clumsiness, at the 36 month
assessment.
The items from the "sub-five" years test were used to assess
the effect of CMV on motor co-ordination. The first two items
(Appx V) were found to be too inconsistently performed by
three-year-olds to be reproducible or comparable. When the
















Adjusted mean Griffiths Developmental Quotient of children with
asymptomatic (no sequelae) and symptomatic (neurological sequelae)
congenital CMV compared with mean of controls.
FIG 2.
possible score was 25. Thirteen cases and 26 controls have now
completed this test, and there is no significant difference in the
mean scores of both groups (Table 19). Although the number
assessed is still small this suggests no increase in clumsiness in
the CMV group and suggests that minimal brain damage is not
occurring in this area of motor skills.
Use of the Stycar Sequence
The Stycar sequences were initially used, as described by Dr.
Sheridan, as a descriptive analysis of the abilities of babies to
identify those at risk of intellectual, motor or sensory defects.
The attempts to score the sequences did not begin until many of the
children had reached two years. The tests were found to be
satisfactory to score. They were simple to perform, required only
minimal equipment and could be performed at home. The sensitivity
and specificity have not been determined in a normal population.
The results of the tests in controls are plotted on fig.3. This
shows that children scored consistently along a quadratic axis
which has been plotted. Fig. 4 shows how the children with CMV
perform compared with the mean of controls. This suggests there
is no difference between the scores achieved by cases and controls.
This is confirmed when the results were subjected to a logistic
regression to remove the effects of age and variation due to
matching variables (Table 20). However, the number of children
with neurological sequelae (six) assessed by this method was small
and so a significant difference between those with neurological
sequelae and those who escaped sequelae was only apparent at 18
months.
When this method of assessment is compared with the Griffiths
test at 24 months, of the six in whom the Griffiths score fell
below 2 SD from the mean of controls, one was not tested by the
Stycar method, three scored poorly (one spastic quadriplegia at 18
months, one fetal alcohol syndrome and one macrocephaly at 36
months). Two had normal scores. One of these was assessed by
Stycar at nine and 18 months when his behaviour problem was not so
apparent as at 24 months when the DQ was performed. The second
scored poorly in the Griffiths assessment but when examined at 36




Tests of motor coordination in children with congenital CMV and
controls.
Mean SD
CMV no sequelae (n.13) 19.69 3.42
p.=0.97









Developmental testing using the Stycar scoring sytem;
mean difference from controls.
Age (months) n. CMV no sequelae n. CMV neurological
(SD) sequelae (SD)
3 15 -1.51 (1.7) 1 0.05 (4.4)
9 23 0.88 (2.0) 2 - 7.23 (5.5)
18 18 -0.51 (2.2) 3 -19.63 (4.8)
36 15 -0.42 (1.8) 2 1.24 (4.8)
The Stycar sequence scoring system, therefore, while less
sensitive than the Griffiths test, was a useful adjunct to the
clinical examination, and was very adaptable to situations where
the Griffiths test was less appropriate. However, the Griffiths
assessment was required to document the abilities of the children
in a reproducible and consistent manner. It was also required to
assess the abilities of the children in specific areas, using the
subscores, so that the particular areas of concern such as language
could be highlighted. The Griffiths assessment will also be used
to compare with IQ tests at five years to assess if children appear
to have a "fall-off" in intellectual development with age as a
result of CMV.
7. ASSESSMENT OF INTRAUTERINE AND LONGITUDINAL GROWTH AND
RELATIONSHIP TO OUTCOME.
As shown in Table 12 no effect of CMV was demonstrated on
intrauterine growth. This analysis did not, however, correct for
factors such as gestation, birth order, maternal social class or
race. The data on intrauterine growth was combined with
measurements of postnatal growth to examine the effect of CMV, in
more detail allowing for these factors, and in particular to assess
if growth retardation was a feature of CMV alone and if it was a
predictor of future outcome. The congenitally infected infants
were divided, as in the Griffiths analysis, into those with or
without permanent neurological sequelae on follow-up. The
standard deviation scores of both groups of congenitally infected
infants and controls for weight, head circumferance and length at
birth, and height and head circumference at three, nine, 18, 24 and
36 months are shown in Table 21.
The variability in the recorded measurements of birth length
was extremely wide and is probably due to difficulties in
performing measurements of this type in the labour ward where no
stadiometer was available. In consequence measures greater than 3
SO from the mean in each group were excluded from the analysis of
birth length. Inspection of these data suggest that CMV, which
does not result in neurological sequelae, has no consistent effect
on both intrauterine and postnatal growth. However, since there
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TABLE 21.
Standard deviation score (SDS) of weight, length and head





Birth 97 -0.17 0.98
Length
Birth 94 0.73 1.48
3 9 0.34 1.36
9 75 0.07 1.33
18 60 0.04 0.95
24 38 0.40 1.06
36 31 0.40 1.01
Head Circumference
Birth 96 0.38 1.16
3 29 0.44 1.08
9 85 0.39 1.03
18 62 0.33 1.19
24 40 0.49 1.07
36 31 0.05 1.32
Congenital CMV
no sequelae neurological
n. SDS SD n.
sequelae
SDS SD
44 -0.02 1.20 6 -1.29 2.09
36 0.44 1.33 4 -0.72 2.27
23 0.22 1.09 3 -0.56 2.28
36 -0.22 1.45 6 -1.03 1.87
23 -0.74 1.35 5 -1.28 1.89
20 -0.32 1.28 3 -1.83 1.71
15 -0.18 1.26 2 -0.13 2.24
44 0.45 1.35 6 -2.69 2.08
26 0.58 0.99 3 0.0 0.40
40 0.25 1.30 6 1 1—» ^>1 2.47
25 0.13 1.20 5 -2.11 2.77
21 0.58 1.70 2 -4.75 4.89
16 -0.14 1.68 2 -1.05 0.58
were wide variations in maternal factors such as race and social
class which could not be corrected for from normative data it is
possible that real differences may not be detected by analysis of
such data by simple unmatched T tests. These data were therefore
subjected to logistic regression analysis to correct for maternal
age, race, social class, parity, marital status and infant sex.
By this measure the difference in SDS between CMV cases in both
groups and controls could be calculated and 95% confidence limits
and significance levels presented.
Birth Weight and Head Circumference.
The results for birth weight and head circumference are shown
in fig.5 and for length in fig.6. It will be seen that there is
no difference in the birth weight of children with CMV,and no
subsequent sequelae, compared with controls. Similarly there is
no significant difference in head circumference of congenitally
infected infants from controls at birth or subsequently, with no
evidence of failure of head growth in older children.
Children with neurological sequelae, as a result of CMV,
however, are of significantly lower birth weight (P=0.01). All
six children in this group had head circumference measured at
birth, at nine months, and five at 18 months, and at each age there
was a highly significant reduction in head circumference
(P<0.0001). Only three children were measured at three months and
a further two children measured at 24 months. These results
therefore probably distort the true picture and, if excluded, there
is no evidence of either "catch up" growth or progressive failure
of head growth.
Somatic Growth.
There was no significant difference in the birth length and
height at three and nine months between children with CMV with no
sequelae and controls (fig.5.) However, there is a trend for the
growth to fall behind controls which becomes significant at 18 and
24 months (P=0.04 and 0.006 respectively) but not confirmed at 36
months. It is possible therefore that these infants are not
thriving as well as expected and this may be an effect of CMV. It
will be interesting to see if this effect is confirmed as more


















Adjusted mean Standard Deviation Score of head circumference
and birth weight of children with congenital CMV with no
























AdjustedmeanStandardDeviatiocorofleng hhildwi congenitalCMVwithnosequelae(J)a dneurol gical sequelae(1)comparedwiththme nfntrols. FIG6.
If CMV infection results in neurological sequelae, then the
infants show reduction in height at birth, 9, 18 and 24 months. The
results at three and 36 months are not significant but the
confidence limits at these ages are very wide. Again it will be
of value to repeat this analysis at a later date with more complete
data.
It does appear, therefore, that CMV, which results in
neurological sequelae, also causes growth failure and microcephaly.
However, when no neurological sequelae result, there is no effect
on head circumference. As yet, it is not clear if CMV, which does
not result in neurological sequelae, has an effect on somatic
growth, but the results suggest that there may be a progressive
effect.
8. PROGNOSIS OF CHILDREN WITH CONGENITAL CMV.
The outcome of all the children in the study and the findings
in the neonatal period are summarised in Table 22. Overall 12% of
children with congenital CMV had a specific neurological defect on
follow-up, two (4%) spastic quadripiegia, three (6%) significant
bilateral sensorineural deafness (ie. requiring hearing aids), and
one (2%) optic atrophy. Reduced intellectual abi1ity without
specific abnormality does not appear to be related to congenital
CMV, as shown by the Griffiths testing. To assess the early
features of congenital infection which may predict handicap, those
with neurological handicap, excluding psychomotor delay, were
compared with those without neurological defects.
None of the maternal characteristics examined appeared to be
related to handicap in CMV children (Table 23). Neurological
sequelae followed infection in all three trimesters of pregnancy
and also recurrent maternal infection (table 24).
Children symptomatic in the neonatal period, and of lower head
circumference at birth, had a poor prognosis (p=0.03 and 0.0002
respectively) (Table 25). When children with symptoms at birth
and reduced head circumference are taken together a good prediction
of subsequent handicap is possible when the criterion used to
assess reduced head size >3 SDS below the mean(p=0.0002). All
children with neurological abnormality were identified at or before
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TABLE22.
Clinicalman fest tionsbir hndtsubsequentfollow-up ofchildrenwithcongenitalCMVandco trols.
Abnormalat birth Nospecific abnormalities atbirthut permanent neurological sequelae SUBTOTAL Normalatbi th butwithout neurological sequelae TOTAL CongenitalKV Controls
AssessmentatBirth No.
43 50 97
BWt (Ji7 5 10%
3 3%
OFC <3%
11 22% 11 11%
CNS Defects 2 4%
Hepato¬ megaly 1 27,
Resp Symp 1 27
Other* 1 2%
Follow-upAssessment Spast- icityVisual Handicap











Outcome in congenital CMV in relation to maternal
characteristics.
n. No sequelae Neurological
sequelae
Maternal <20 16 12 4
age: 20-24 17 17 0
25+ 17 15 2
Race As i an 4 3 1
White 32 29 3
Black 14 12 2
Social Non-manual 23 19 4
class: Manual 11 10 1
Other 16 15 1
Parity Para 0 32 26 6
Para 1+ 18 18 0
Marital Single 23 18 5
Status: Married/ 27 26 1
Cohabiting
Total 50 44 6
TABLE 24.
Outcome of congenital CMV in relation to type and gestation of
maternal CMV infection.
Maternal Gestation n.(%) Neurological
infection weeks sequlae n.(%)
<16 9(18) l(ll)xx
Primary 16-27 7(14) 1(14) x
>27 14(28) 1( 7)+













Outcome of congenital CMV in relation to features noted at birth.














Mean SDS HC (SD) -0.49(1.35) -2.69(2.08) 0.0002
Mean SDS Weight (SD) -0.07(1.2) -1.29(2.09) 0.2>0.1
0.0002
the nine month assessment and hearing test. This suggests that
normality at this age is an excellent prognostic feature though the
number of children seen in the older age groups is still not
substantial.
Virological Measures
The persistence of viral excretion was not helpful in
predicting handicap since most children continued to excrete CMV in
the urine at least up to 24 months (Table 26). The measurement of
CMV specific IgM in cord blood samples, when available, was also
compared with both subsequent handicap and the timing of maternal
infection (Table 27). Unfortunately, not all the samples were
tested in the same assay, so are not strictly comparable.
However, the pattern suggests that high IgM titres of >3000 are
more frequent in primary infections after 28 weeks gestation and
low titres of <1600 are common before 28 weeks. There was no
consistent relationship with neurological sequelae (table 28).
9. COMPARISON BETWEEN CHILDREN WITH CONGENITAL CMV AND THE STUDY
POPULATION.
The estimated number in the study population and the number of
children with congenital CMV in each group is shown in Table 29.
The estimated prevalence of congenital CMV in the study population
is shown by maternal age, race, marital status, parity, social
class and infant sex. Maternal age, marital status, race, social
class and parity were all associated with an increased prevalence
of congenital CMV. To explore the independent effect of each of
these maternal characteristics, the prevalence of congenital CMV
was calculated for each, taking account of the other variables.
For this purpose, mothers of 25 years and over were grouped
together as the prevalence rates in the older age bands were the
same. When analysed by maternal age, the prevalence amongst
blacks born in the U.K., Africa, and the West Indies were similar,
so all three origins were analysed together. Asian mothers (ie.
of Indian sub-continent origin) were excluded as the number in this
category was too small to be further sub-divided.
The maternal characteristics with the strongest effect on the
rate of congenital CMV were age, race and marital status. Once
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TABLE 26.
Outcome of congenital CMV in relation to persistence of viral
excretion:number of samples collected (% positive).
Age - months 3 9 18 24 36
No sequelae 52(90) 32(84) 21(71) 12(75) 12(58)
Neurological 4(100) 4(75) 3(66) 1(100) 1( 0)
sequelae
Total 56(91) 36(83) 24(70) 14(71) 13(54)
TABLE 27.
CMV specific IgM titre in relation to gestation and type of
maternal CMV infection.
Titre Primary infection: Recurrent
weeks gestation infection
<16 16-27 >27
<50 0 2 0 0
100-800 0 1 0 1
800-<1600 1 2 1 0
1600-<3000 0 0 1 0
3000-<6400 0 0 1 1
6400 0 0 3 0
Total 1 6 6 2
TABLE 28.
Outcome of congenital CMV in relation to CMV specific IgM titre
in cord blood samples.
Titre Neurological No sequelae
sequelae
<50 0 3







The estimated prevalence of congenital CMV infection by maternal





Asian 2230 4 1.79
White 18525 32 1.73
B1 ack 2099 14 6.67
Marital status
single 3107 23 7.40
Married/cohabiting 20471 27 1.32
Age
<20 1863 16 8.59
20-24 5268 17 3.23
25-29 7731 8 1.03
30+ 8790 9 1.02
Parity
Para 0 11872 32 2.70
Para 1+ 11771 18 1.53
Social Class
Non-manual 12901 22 1.70
Manual 8128 12 1.48
Other 2549 16 6.28
Infant sex
Male 11984 26 2.17
Female 11646 24 2.06
these were accounted for, parity had no appreciable effect except
that in 20-24 year old married white mothers the prevalence of
congenital infection among multiparous women was 7/1280 compared
with 1/1824 in nulliparous women. In view of the number of
possible comparisons this could be a chance finding.
In Table 29 mothers in the "other" social class group show a
higher rate of congenital CMV than mothers in either manual or
non-manual social classes. Social class was assessed by paternal
occupation, or maternal occupation in single mothers. The "other"
group included students, the unemployed and single mothers with no
definable social class. Amongst white mothers, within each age
group, the rate of congenital CMV was similar in all three social
groups. However, amongst black mothers, although there does not
appear to be an effect of social class, when age is accounted for,
the numbers in some subgroups were too small to completely exclude
an effect.
The prevalence of congenital CMV by maternal race, marital
status and age is shown in Table 30. Since these factors are
closely interrelated, these data were subjected to grouped logistic
regression to assess the independent contribution of each factor.
The results are shown in Table 31. All three maternal
characteristics have a significant effect on the rate of congenital
CMV even after adjustment for the other factors. There were no
significant interactions between these factors: so, for example,
the effect of marital status is constant for all ages and races.
The risk of a black mother giving birth to a child with congenital
CMV is estimated to be 2.1 times that of white mothers. Similarly
single mothers have an increased risk of 2.5 compared with
married/cohabiting mothers, and mothers under 20 years an increased
risk of nearly four times that of mothers over 25 years. These
risks multiply such that a young single black mother has a risk
approximately 20 times the risk for a married white woman over 25
years.
The above data includes all infants with congenital CMV and
does not distinguish between those born following primary and
recurrent maternal infections. It was possible to define the type
of maternal infection in 42 cases (Table 32). When analysed by
race and age the numbers were too small to demonstrate a
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TABLE 30.
Congenital CMV by maternal race, marital status and age;
rate per 1000 live births.
Age 14-19 20-24 25+






5/656 7.6 5/665 7.8 1/855 1.2
0/610 0.0 8/3102 2.7 13/12720 1.0
B1 ack
Single 8/312 25.6 2/301 6.5 1/249 4.0
Married/ 1/53 8.9 1/362 2.8 1/799 1.3
cohabiting
TABLE 31.
Risk of congenital CMV related to maternal age, race
and marital status
Age:(p<0.01) Relative risk (95% C.I.)
25+ years (reference) 1
20-24 years 1.5 (0.7 - 3.3)
14-19 years 3.9 (1.8 - 9.1)
Race:(p<0.05)
White (reference) 1
Black 2.1 (1.1 -4.1)
Marital status:(p<0.02)
Married/cohabiting (reference) 1
Single 2.5 (1.3 - 5.1)
TABLE 32.
Type of maternal CMV infection resulting in congenital infection:
relation to maternal age and race.
Age 14-19 20-24 25+ Total (%)
White: Primary 5 9 11 25
Recurrent 0 1 2 3 (11)
B1ack: Primary 6 1 0 7
Recurrent 2 2 1 5 (42)
Asian: Primary 0 0 0 0
Recurrent 0 1 1 2 (100)
All Primary 11 10 11 32
races: Recurrent 2 4 4 10 (24)
significant pattern but recurrent infections are most frequent in
older women and non-caucasians.
The frequency of previous exposure to CMV infection in the
screened population was available in 8059 women and the data
presented in fig.7. The prevalence of CF antibody was consistent
in the Asian mothers at all ages. In both black and Caucasian
mothers the seropositivity rate rose considerably with age. In
black mothers from 68% in women under 20 years to 86% in women over
30 years. In Caucasian women the rates rose from 38% to 52%
respectively.
10. THE TRANSMISSION OF CMV INFECTION IN FAMILIES OF CHILDREN WITH
CMV INFECTION.
Eight family groups have been studied, seven with a
congenitally infected infant and one where the infant acquired CMV
while in hospital (figs.8,9).
Families 1-4 and 7 consisted of both parents and an older
sibling in each case. In families 1,3,4, and 7 the mother had
experienced a primary infection during pregnancy. In the
remaining family (2) the mother experienced a presumed recurrent
infection, being CMV CF antibody positive at 11 weeks gestation
with no demonstrable CMV specific IgM antibody.
Families 5 and 6 consist of parents and congenitally infected
child only. In each case the mother had experienced a primary CMV
infection.
Viral excretion by mothers of congenitally infected infants.
In six of the seven families virus was isolated from mothers
of congenitally infected infants. In three from urine only and in
the remaining three from breast milk in addition to urine. The
period of maternal virus excretion was short in each case. In
family 6 endonuclease typing has shown no dissimilarity in the
viruses isolated from mother and baby confirming vertical
transmission (fig.10). However, in family 7, virus isolated from
mother's breast milk, whilst showing an identical pattern with
enzyme Hind III, shows minor genetic variation with enzyme Bgl III
(fig.11,marks a,b). This suggests a minor genetic change as a
result of passage to a different host.
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Oligonucleotide patterns of CMV DNA from families 7 and
DNA was digested with enzymes Hind III and EcoRl:
Family 7 :Lane 3 - virus from infant's urine
Lane 4 - virus from mother's breast milk
Family 8 :Lane 5,6,7 - virus from 3 siblings
Lane 8 - virus from infant's urine
FIG 11.
Acquisition of CMV by fathers.
In four fami 1 ies,(1,2,6 & 7) the father was CMV antibody
positive when first tested after the birth of the congenitally
infected infant but virus was not isolated and it is not possible
to confirm the source of infection. In families 3 and 4 the
father did not acquire CMV during the period of study (eight and 25
months respectively.) Both were exposed to their congenitally
infected sons excreting high titres of virus continuously for the
study period and partners who had experienced a recent primary
infection.
One father, in family 5, sero-converted 16-36 weeks after the
birth of a congenitally infected daughter. Unfortunately
specimens for viral culture could not be obtained so it is not
possible to define an intrafamily source of CMV.
Acquisition of CMV by siblings.
None of the five siblings studied were positive on virus
culture at the time of the birth of the congenitally infected
sibling. However, two (in families 2 & 3) acquired CMV after
three and four months exposure respectively. The other three were
negative after four, 18, and 25 months exposure respectively. DNA
endonuclease typing of isolates of the two contacts demonstrate a
nondissimilar genetic structure compared with the virus isolates of
their congenitally infected siblings, suggesting intrafamily
transmission had occurred, probably from the younger infant, but
spread from the mother cannot be excluded.
CMV infection following hospital acquired CMV.
Family 8 provided an opportunity to study a family with only
one known source of CMV infection. The family consisted of
parents and four children. The fifth child (Antony) was delivered
at 30 weeks gestation following severe rhesus isoimmunisation.
Two intrauterine transfusions were required before birth, three
exchange transfusions within 48 hours of birth and three further
transfusions to treat anaemia at 20, 32 and 42 days. The last
three transfusions were donated by fit hospital staff and the
donors of the last two transfusions were known to possess CMV CF
antibodies. Congenital CMV was excluded as part of the
prospective study and CMV CF titre was <5 at 30 days. CMV was
isolated at 60 days from urine suggesting acquisition from one of
- 64 -
the last two blood transfusions. Despite this he was asymptomatic
and discharged at 67 days. He continues to excrete high titres of
CMV in urine after 20 months.
His mother seroconverted within the first five months since
his discharge and his father between five and 13 months. (The
absence of CMV specific IgM suggests primary infection occurred
five to nine months after discharge.) Unfortunately virus was not
isolated from either parent to confirm the source of infection.
During the period of study three of four siblings have excreted
CMV. The viruses of all three siblings were demonstrated by DNA
endonuclease typing to be genetically not dissimilar but distinct
from the virus excreted by Antony suggesting a source infection




This study is the first large prospective study of congenital
CMV in Britain. Only the Collaborative Study 127 has studied
f
similar numbers of children with congenital CMV from a British
population. However, the nature of that study was not
prospective, and so the results are difficult to apply to other
populations. The present study provides the prospective data to
estimate the effects of congenital CMV on a British population.
Using these data, decisions may be made on the advisability of
screening for CMV in pregnancy and screening neonates.In addition
the need for preventive measures, such as vaccination, may be
assessed. The final results of the population study 153,from
which this cohort of congenitally infected infants was derived,will
allow rates of primary CMV infection in pregnancy, rates of
congenital infection, and frequency of intrauterine transmission to
be calculated.
The rate of permanent neurological sequelae in infants with
congenital CMV, in this study, was at least 8-12%. This includes
10% with sensorineural deafness, 4% with spastic quadriplegia and
2% with visual handicaps. These results are similar to other
prospective studies in USA, 83,103,167 Canada 175 and Sweden _1
despite the wide variation in the prevalence of congenital
infection throughout the world.
THE EFFECT OF DIAGNOSTIC METHODS ON THE RESULTS.
It has been shown that the method of diagnosis of congenital
infection may have profound effects on the prevalence rates and
type of congenitally infected infant selected. 4,83,131,167 The
diagnostic method used here, virus isolation from a throat swab,
was the only feasible method of screening such a large population.
This method has a false negative rate of 12%. To reduce the
effect of this, urine samples were collected in the infants of
mothers who seroconverted prior to delivery. Some infants with
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congenital infection will, however, not have been included in the
study as the throat swab was falsely negative. Infants of mothers
who were seropositive at booking following early primary infection
or maternal reactivation will thus be under-represented by 10-15%.
When combined with the seroconversion group the overall rate of
false negative results would be 8% in the study as a whole.
It is noteworthy, however, that occasional problems in virus
culture from urine samples mean that false negative results may
occur with this method. Screening, using samples of cord sera, to
detect CMV specific IgM, is the least satisfactory method, as
illustrated by the two studies on the same population. 131 The
only advantage of screening by this method, is that large numbers
of samples may be collected and stored for analysis in batches
later, or retrieved for testing in children found to have
sensorineural deafness or other neurological problems in later
life, when virus isolation cannot distinguish between congenital
and acquired infection. 166
It is felt, therefore, that the results of this study may be
compared with other prospective studies despite differences in the
diagnostic method. 1,83,167,175,205
THE USE OF CONTROLS TO ASSESS THE EFFECT OF CONGENITAL CMV.
Controls were selected in all but two cases. Two controls
were selected in each case, to guard against the possibility of
loss of contact. In the three years of the study, only six
controls have lost contact after varying follow-up periods. The
controls were adequately matched for infant sex, maternal race and
age. In many cases, matching on the second line criterion was
possible and no differences were found between cases and controls.
However, to reduce the variability in some analysis it was
appropriate to use regression techniques. In this form of
analysis allowance can be made for differences in background
characteristics so that the full effect of CMV on the variable,
such as developmental quotient or growth, could be assessed.
While this method did not detect any significant differences not
apparent on inspection, it allows a more confident prediction of
the effect of each variable. Thus, for example, it can be seen
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that the mean DQ of a child from manual social class is 6 points
below the expected mean of children of non-manual social class.
The effect of CMV with neurological sequelae is, however, much more
significant, reducing the mean DQ by 35.6 points. By this method,
then, it can be confidently stated that, in this example,
congenital CMV not associated with neurological sequelae does not
significantly effect intellect, and so counter claims that
congenital CMV may account for a significant number of children
with mild mental handicap, dyslexia and minimal brain damage who
previously had no diagnostic label. 84 Similar arguments explain
the need to use this type of analysis of data on growth so that the
effect of socioeconomic factors may be distingished from the effect
of congenital CMV.
ANTENATAL PROBLEMS ASSOCIATED WITH CMV.
No increase in antenatal problems was noted in the mothers of
children with congenital CMV. None had symptomatic infection
suggestive of maternal CMV. Infants with congenital infection,
who subsequently went on to develop normally, did not suffer any
retardation of intrauterine growth. It is possible that some
fetal loss may occur as a result of maternal primary CMV 72 but
there is no evidence from this or other studies that premature
labour is precipitated by CMV. 205 It has been suggested that
infants with CMV may be of lower birth weight. 205 This is so in
infants who subsequently develop neurological sequelae, who are
frequently symptomatic at birth, 146 but there appears to be a
clear distinction between this group and those who subsequently
develop normally, rather than continuous effect on birth weight.
SFGA infants were not significantly more frequent amongst infants
with congenital CMV compared with controls and it is of little
value screening SFGA infants for CMV. 163 Similar findings have
been reported in rubella. 115 Severely affected infants are,
however, often small, and, in particular, have microcephaly.
146,232 Congenital abnormalities ocurred no more frequently than
expected and it is probable that earlier reports of an association
were due to chance occurrences. 15,122,125,205 There is little
evidence of a teratogenic role of CMV infections in pregnancy.
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INFANTS SYMPTOMATIC IN THE NEONATAL PERIOD.
Three infants were ill in the neonatal period and in two
congenital infection was suspected. One suffered extreme growth
retardation and dystonia as a neonate, the other hypotonia and
hepatomegaly. Both developed significant handicaps on follow-up.
One further child had pneumonitis, retrospectively attributed to
CMV. Thus 6% had neonatal symptoms and two thirds subsequently
developed neurological handicaps. These findings are in accord
with most other studies. 113,131,146,205,232 No child in this
study, however, presented with hepatosplenomegaly, purpura, and
thrombocytopenia; the commonest combination of presenting features
described in cytomegalic inclusion disease. 125,146 Two
children, however, developed hepatosplenomegaly in the first three
months and, as described by McCracken et al, 125 this persisted
for up to eighteen months in one child, followed by complete
recovery. Later presentations of this type have only previously
been noted by Starr et al. 205 Since congenital infection was
not suspected in either case, these features may have been missed
had the children not been followed prospectively.
RESPIRATORY COMPLICATIONS OF CONGENITAL CMV.
The role of CMV as a respiratory pathogen is only now being
recognised. No other prospective study has described pneumonitis
as a problem in congenital CMV. This complication occurred in 12%
of infants in this study. It is recognised that organisms such as
CMV, chlamydia and Pneumocystis may give rise to opportunist
infections in the first few months of life. 198 These often
present, as in this study, at 3-4 months, when passively acquired
maternal antibody levels start to wane. Double infections are
common, as in one child in this study with coincident chlamydial
infection. All of the infections in this study were mild, and
would not routinely have been investigated. This may be why
pneumonitis has not previously been reported in congenital CMV
after the neonatal period.
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CMV pneumonitis is not always benign and severe infections may
occur, particularly in infants with other problems such as broncho¬
pulmonary dysplasia. 229 It is possible to treat severe cases
with high titre CMV specific immunoglobulin, so correct diagnosis
is important. 186
MAJOR NEUROLOGICAL HANDICAPS RESULTING FROM CONGENITAL CMV
In the present study 2 children (4%) developed spastic
quadriplegia, a rate similar to other prospective studies. (2-6.6%)
4,83,166,175,205 As would be expected from previous studies 195
one child ,with cerebral palsy, also suffered from optic atrophy
(2%). No other specific neurological complications have been
noted as yet, other than sensorineural deafness, but it is possible
that minor neurological handicaps such as those described by
Williamson et al 232 may become apparent in the older children.
The number of children who have reached the three-year examination
is still small as yet but no evidence of specific problems such as
language disorders are so far apparent. In the Griffiths testing
all subscores gave similar results to the total score and the Stott
test demonstrated equal coordination abilities in congenitally
infected infants and controls.
Sensorineural deafness is the commonest neurological sequelae of
congenital CMV, the rate in this study being 10%; 6% were
significant bilateral (ie. hearing loss of 60 dB in the better
ear.) All of these children require hearing aids and will require
special educational help. Previous studies reported rates of
deafness of up to 50% of cases of congenital CMV. 167 However,
when analysed in more detail it is apparent that some of the
figures were elevated due to the diagnostic method and very wide
definition of "deafness". When the same population was restudied
by Stagno et al, 199 with the use of the more sensitive screening
test for congenital CMV (isolation of virus from urine samples),
the rate of deafness was found to be 7.7%, similar to that reported
here. However, it is not possible to be confident that all cases
of unilateral deafness have been identified as yet, since very few
children in this study were mature enough to have a full
audiometric assessment with the use of headphones and masked bone
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conduction. The two reported with unilateral deafness were
diagnosed by distraction testing, and require confirmation later.
Finally the possibility of progressive deafness requires further
study. 36,232 Other prospective studies have not reported
progressive deafness and Saigal et al 175 tested most of their
subjects twice, at 3 and 5 years, with no significant change in
results. It is therefore mandatory to retest all children in this
study at 5 years.
The effect of CMV on intelligence is still not clear. For
some years it has been suggested that CMV is a major cause of
mental handicap. 48,84,131 CMV certainly causes severe mental
retardation in conjunction with major neurological handicaps such
as spastic quadriplegia as in two cases here. However, only one
prospective study has shown a significant effect of CMV on IQ. 83
Indeed, in that study social class had a marked effect, and it is
possible that there was an additive effect. Also several children
with other neurological handicaps which may have affected their
performance were not excluded. The regression analysis of
Griffith testing in the present study demonstrates that social
class certainly has an effect on DQ which is significant and
independent from the presence or absence of CMV. There was no
interaction between these variables. These data, combined with
the negative findings of Saigal et al and Kumar et al and the
equivocal findings of Reynolds et al do not suggest any effect of
CMV on intelligence, when neurological disabilities are allowed
for. 107,167,175 Indeed, the pathological findings in
congenital CMV are mainly specific, localised lesions, which are
likely to produce specific effects, inner ear involvement causing
sensorineural deafness, periventricular foci causing upper motor
neurone effects, and chorioretinitis and optic atrophy causing
blindness. These features are distinct from the toxic effects of
poisons such as alcohol and lead, 174,246 both of which cause dose
related effects with mild to moderate reduction in overall
intellectual abilities, often in the absence of specific
neurological features. This is illustrated by one congenitally
infected child in the present study, who also suffered from fetal
alcohol syndrome. She is now over three years old, and below the
third percentile for height, weight and head circumference with
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mild mental retardation, but there is no specific neurological
defect. It is possible that the major pathology in this child is
fetal alcohol syndrome, and that congenital CMV is incidental.
THE EFFECT OF CONGENITAL CMV ON GROWTH
Infants with symptomatic congenital CMV are often growth
retarded 146 and microcephaly is a poor prognostic sign at birth.
In the present study children who subsequently developed
neurological sequelae were significantly shorter, of reduced birth
weight and head circumference. There was no evidence of
subsequent catch-up growth in these children. In addition, it has
been demonstrated that a head circumference of more than 3 SD below
the mean carries a poor prognosis.
Since the intellectual progress of infants with congenital
CMV, but no subsequent sequelae, is similar to controls, it is not
surprising that birth weight and head circumference are also
similar to controls. The height of these children, however, did
not match the other parameters. There was no difference in birth
length and length at three months, but mean height gradually fell
below the expected mean at 9, 18, and 24 months, the difference
becoming significant at 18 and 24 months. This was an unexpected
finding and has not been noted in congenital CMV before. The full
cohort have not yet reached the older age groups so the results are
by no means confirmed and indeed the trend is reversed in the
fifteen children measured at 36 months. This suggested effect of
congenital CMV does not match the pattern of CMV defects described
up to now. It is extremely important to follow this group
sequentially and reanalyse the data when they reach five years.
THE EFFECT OF TYPES OF MATERNAL CMV INFECTION.
It was possible in this study to establish the type of
maternal infection in all but 16% of cases. This compares
favourably with Ahlfors et al who was unable to classify the
type of maternal infection in 42% of infants with congenital CMV.
The use of the RIA to detect CMV specific IgM, in association with
recent primary infection, was crucial in improving the specificity
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of the test. The demonstration of IgM by this method in 86% of
primary infections within 16 weeks of seroconversion and absence
after 16 weeks 98 means that the presence or absence of CMV
specific IgM can be used to classify a large group of women who
present for antenatal care with CMV CF antibodies detectable, but
no previous samples available to determine when seroconversion
occurred. 74 This test has now been applied to screening in
pregnancy for early primary infection as well as its retrospective
use demonstrated here.
Taking into account the problems of screening, using the
collection of throat swabs and the false negatives of the IgM
assay, the relative contribution of primary infections was 76% and
recurrent infection 24%. There was no significant difference in
the rate of congenital CMV following primary maternal infection in
each trimester, (1-30%, 11-23%, 111-46%) and the rate of primary
infection is probably constant throughout pregnancy. T6
It is not possible to estimate the stage of pregnancy at which
women experience reactivation of CMV and transmit infection to the
fetus. Even if CMV is cultured from cervix or urine this does not
mean that the fetus is infected at the time of positive virus
culture, as transmission may result from local extension of
infection in the cervix or endometrium, and not from viraemia.
Thus it is possible to assess the effect of infection at each stage
of pregnancy following maternal primary infection but not following
recurrent maternal infection. However, there is no evidence from
this study that gestation of primary infection has an effect on
outcome. The rates of subsequent handicap are similar following
maternal infection in all three trimesters and confirms the
findings of Stagno et al. 201 Ahlfors et al (5 did note more
symptomatic infections following first trimester infections but
this data was drawn from collaborative work, where only one child
was identified in her prospective study, and the rest were referred
presumably because of clinical suspicion of intrauterine infection.
The small number of prospective studies, 5,201 which have
been able to define the type of maternal infection, does mean that
it is not yet possible to be confident of the role of maternal
reactivation in relation to subsequent outcome in congenital CMV.
There are, however, four case reports of handicap following
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confirmed maternal reactivation. 3,87,173,239 Two infants with
sensorineural deafness, one with additional spastic quadriplegia,
in the present study were born following presumed maternal
reactivation. Unfortunately, since the RIA test of CMV specific
IgM is only 86% sensitive 98 it is not possible to exclude the
possibility that both these mothers may have experienced early
primary infection with an absent or unusually transient rise in
IgM. The rate of handicap, however, is similar in all studies,
despite wide variations in the population screened, with wide
ranges of seropositivity in the maternal population. 215 This
suggests, irrespective of the proportion of congenital CMV arising
from maternal primary infection and reactivation, the outcome is
si mi 1ar.
OVERALL EFFECTS OF CONGENITAL CMV ON A BRITISH POPULATION
Children with congenital CMV in this study can be divided into
two separate groups. The majority, ie. 44 of the 50 children
(88%) have suffered no significant permanent sequelae resulting
from congenital CMV infection. The remainder (12%) have longterm
sequelae, unilateral deafness in 4% and major handicaps such as
spastic quadriplegia, bilateral sensorineural deafness in 8%.
Only two early features were associated with eventual poor outcome,
symptoms of intrauterine infection in the neonatal period or head
circumference more than 3 SD below the expected mean. Other
features previously associated with poor outcome, type of maternal
infection, 201 gestation of primary infection, 6,136 high titre
of CMV specific IgM in cord blood, _75 were not confirmed. Indeed
it may be that the IgM titre, in cord blood, is more commonly a
reflection of the time since primary maternal infection than a
measure of severity. The titre of virus excretion, in the urine,
has also been associated with a poor prognosis, 75^ but this
measure of viral activity was not available in the present study.
However, the majority of infants in both groups excreted virus
consistently for at least two years, by which time all
neurologically affected children had been identified clinically.
While most children, who developed problems later, could have
been identified at birth, one child with sensorineural deafness was
- 75 -
apparently entirely normal up to the age of six months. It is not
possible, therefore, to be entirely confident that all those who
will have problems later may be identified at birth.
It is possible now to predict the impact that congenital CMV
may have on a British population. Assuming a birth rate of
650,000 per year, in England and Wales, and a rate of congenital
CMV of 3-4/1000 live births, 127,153 1950-2600 infants will be
born with congenital CMV per year in Britain. Assuming 10% have
appreciable deafness, neurological defects, or both, 195-260
infants will be born each year with serious handicaps. If a
further 5% have minor handicaps such as unilateral deafness, the
total number of children affected will be 3-400. Hence the number
of children with serious handicaps attributable to cytomegalovirus
is comparable to that of children born with congenital rubella
defects in a non-epidemic year, prior to the vaccination era. 46
SCREENING FOR CMV INFECTION IN PREGNANCY AND NEONATES
It has been suggested that the best method of control of
congenital CMV is to screen in pregnancy for primary infection and
then to terminate the pregnancies affected. 10 This advice was
based on a number of assumptions of CMV in pregnancy. Firstly,
that reactivation was not associated with congenital infection and
secondly, that as in rubella, early CMV was more likely to cause
serious handicaps than infections in later pregnancy. This advice
is no longer tenable.
In an audit of their screening programme of primary CMV
infection in pregnancy, Griffiths and Babbonian 76 have
demonstrated that, since at least 50% of primary infections are not
transmitted in utero and a large number of infections cannot be
diagnosed early enough to allow termination to occur, many
uninfected infants and congenitally infected infants who will not
develope sequelae, will be lost, but a significant number of
congenitally infected infants who will subsequently be handicapped
will be missed should such a policy be instituted. In the present
study the most seriously handicapped infant was born following a
maternal primary infection diagnosed by the presence of CMV
specific IgM at 28 weeks gestation when the mother first presented
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for antenatal care. Reviewing the data in this study in
retrospect, only four cases of seroconversion were identified
before 28 weeks gestation and the infants of all four mothers have
asymptomatic congenital infection. The other mothers experiencing
seroconversion before 28 weeks gestation were only diagnosed in
retrospect.
In addition to the 18 infants born following seroconversion,
the mothers of the remaining 63% of congenitally infected infants
were seropositive at booking and at least 20% were born following a
maternal reactivation. At present, there is no serological method
of diagnosis in maternal reactivation, as the antibody response to
recurrent infection has not yet been clearly defined. Virus
isolation in seropositive women represents evidence of reactivation
but may bear no temporal relationship to when, or if, the infant
may acquire infection in utero. Thus, screening in pregnancy will
also be ineffective in identifying all women at risk of delivering
a congenitally infected child.
It has been demonstrated here that screening of neonates is
practical but since there is no treatment available it is debatable
whether this is justifiable. It will allow the identification of
a group at risk of developing sensorineural deafness, but 80-90% of
these infants will develop normally. If there is an effective
screening service to identify early problems with hearing or
psychomotor development then those with problems will be offered
prompt treatment without requiring prior identification of CMV.
In addition, screening for CMV will subject the parents of the
majority 80-90% of congenitally infected infants to at least a year
of anxiety until they can be sure their child will not suffer as a
result of this infection. Therefore, unless a safe, effective
antiviral preparation can be produced, there is little
justification in screening for CMV in pregnancy or among neonates.
It may, however, be of value to store neonatal blood samples to aid
in the diagnostic screening of children who present later with
neurological handicaps. Congenital CMV may account for up to 20%
of all cases of sensorineural deafness and positive diagnosis of
viral etiology can allay fears in parents that future children are
likely to suffer from genetically determined deafness.
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THE PREVALENCE OF CONGENITAL INFECTION IN SUBSECTIONS OF THE
POPULATION
The results in this study confirm the prime importance of
maternal age in determining the prevalence of congenital CMV
113,127,201,205 and the lesser effect marital status. 113,127 It
also highlights the increased prevalence of congenital CMV in the
infants of black women, which is predictable from the study of
primary CMV by Griffiths et al. 77. None of these studies used
regression techniques to exclude correlations between variables.
This may explain why other suggested associations such as social
class 83 and parity 113,205 are not confirmed here. Reduced
parity is intimately linked with younger maternal age and it has
been shown here that the determining factor is age rather than
parity. Indeed, there is some evidence that increased parity may
increase the risk of acquisition of primary CMV in mothers of
children attending a day nursery. 150
The association of social class described by Hanshaw et al 83
may be a reflection of the method of social stratification 9()
using educational criteria as well as profession. Thus most young
single mothers will be in the lower social class group. These
mothers are unclassified under the Registrar General's
classification 165 and are defined here as "other" social class.
However,the increased prevalence in this group is accounted for in
the regression analysis by maternal age, race, and marital status.
The prevalence of congenital CMV depends on a complex inter¬
relation of several factors. The rate of primary maternal CMV and
the rate of intrauterine transmission will vary depending on the
population studied. Similarly, the rate of maternal reactivation
is also very variable and we still have no measure of rate of
intrauterine transmission in this situation. Thus the rate of
congenital infection in a particular community will depend on the
age, race and marital status of the pregnant population, the rate
of previous maternal CMV infection, and the rate of primary
infection. An expression of both of these is the seropositivity
rates in the community. The number of seropositive women at each
age determines the number of women at risk of reactivation of
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previous infection and the rate of rise of seropositivity is an
expression of the rate of primary infection.
In the present study, the seropositivity rate rose rapidly in
younger women, particularly between the under 20 years and the
20-25 years groups. Thus it may be inferred that the rate of
primary infection is higher in younger women. The rate of primary
infections is higher in black women compared to white as they have
a greater chance of contact with a seropositive partner. The rise
in seropositivity rates slows in the older age groups so fewer
women are experiencing primary infections. This may be because
older women have fewer contacts, despite the increased possibility
that the contacts she has are more likely to be seropositive.
The commonest method of spread of CMV, in adults, has not yet
been defined. There is an abrupt rise in seropositivity rates in
the late teenage years, a rise not seen in nuns. 39 This
suggests that intimate contact, either oral or sexual, is required
for transmission and the number of partners may be relevant. Thus
the social behaviour of young women may determine the rate of
acquisition of CMV, and different social behaviour patterns in
subsections of the population may, in part, account for the
different rates between single and married women, and between
racial groups.
Reactivation of maternal infection is closely linked with
recent primary infection but may also represent reinfection from a
different source. 101 Since the seropositivity rate among black
mothers is higher than whites, it is not surprising that congenital
infection is significantly more frequent following maternal
reactivation in black women, compared with whites. Several
studies have suggested a direct link between seropositivity and
congenital infection rates. This is true when comparing Ivory
Coast 180 and Chile 202 with Britain 208 and Canada. 113 Also
within a community comparing low socioeconomic class blacks and
middle class whites in Alabama.
However, there are significant exceptions. Firstly, in
Japan, where a universally high seropositivity rate is matched by a
low rate of congenital infection. 9I> A similar finding in this
study is the low prevalence of congenital CMV in infants of Asian
mothers in association with a 90% seropositivity rate. All
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congenital infections in the Asian population and those studied in
Japan resulted from maternal reactivation. Thus the 10% of
seronegative women in those communities rarely seroconvert during
the childbearing years, despite contact with a population who are
90% seropositive. Secondly, the rate of reactivation is not high
in the Asian population, compared with lower socioeconomic class
blacks in the Southern USA. 201 This suggests that factors other
than seropositivity determine the rate of reactivation, such as
nutrition, immune competence, or perhaps the likelihood of direct
exposure to active infection with resultant reinfection. The
effect of affluence on a highly seroimmune population requires
further study to determine the frequency of reactivation of CMV
infection.
These findings are important for two reasons, firstly
predictions of the number of infants born with CMV will require
modification to account for the race, age and marital status of the
population as a whole. There is no evidence that the infants of
different groups are selectively more likely to develop sequelae as
a result of congenital CMV, so areas with high concentrations of
young black mothers may have a very high rate of congenital
deafness resulting from congenital CMV. This is analogous to the
concentration of rubella defects in the children of West Indian
immigrants in Britain in past epidemics. Secondly, control
measures such as vaccination will be ineffective if they are
developed purely to prevent primary maternal infection. It may be
that acquisition of infection in childhood may be more protective
against intrauterine transmission in later pregnancy in an affluent
society.
INTRAFAMILY SPREAD OF CMV INFECTIONS
DNA endonuclease typing confirms the finding of Huang et al
91 that congenital infection in infants is aquired from mothers,
although minor genetic differences did appear in oncmother/chi1d
pair, suggesting minor genetic adaptation to the new host. These
differences however are quite distinct from major differences seen
in non-epidemiologically related strains. The DNA patterns are
unique to each epidemiologically related strain with no overlapping
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yet reported.
The study of fathers in families with a congenitally infected
infant cannot confirm if infection was acquired from the infant or
the mother, but in two families the fathers remained seronegative
after 8 and 24 months respectively. This shows that transmission
is not inevitable despite the presence in the family of at least
two potential sources.
In studying siblings, it was thought unethical to subject
children to blood samples to assess their previous exposure to CMV,
thus when virus was isolated it was not possible to determine when
primary infection occurred. Typing confirms intrafamily
transmission either from mother or congenitally infected sibling.
It is possible, however, that the sibling may have acquired
infection outside the home, then transmitted virus to the mother.
Since children with acquired CMV excrete virus for prolonged
periods, 192 and both infants were CMV negative initially, it is
probable that infection was transmitted from mother or congenitally
infected child to older sibling. The inevitability of intrafamily
infection may not be assumed, however, as shown in family 8, where
multiple sources were responsible for family infection.
These family studies illustrate the low infectivity of CMV
except in situations of prolonged contact and would argue against a
significant risk of acquisition by professionals such as nurses and
teachers. The results of studies of the risk of aquisition of CMV,
in a professional situation, using primary infection rates and sero-
positivity are equivocal. One such case (6) was investigated in
the present study and occupational acquisition was excluded. The
only situation of major risk is a primary care giver who is
seronegative caring for an infected child at home. This will
arise if a congenitally infected child goes into foster care. It
will also occur when a premature infant of a seronegative mother
acquires CMV by blood transfusion, following which there is a very
high maternal seroconversion rate. 242 In other situations,
routine hygiene methods should be sufficient to prevent
transmission. 244
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PROBLEMS WHICH REQUIRE FURTHER STUDY
This study has defined the major consequences of congenital
CMV in a British population. Several problems require further
study. The present cohort requires follow-up for some years to
confirm that no other major handicaps come to light, and that those
normal, so far, remain entirely normal. Further study is also
required to define the exact rate of minor hearing defects, visual
handicaps, and exclude effects of congenital infection on higher
intellectual function, such as intelligence, specific language
defects, learning disorders and behaviour. The growth of
otherwise asymptomatic children requires further study to define
the importance of the preliminary effect on growth shown here.
It will be some time before sufficient children have been
followed up in this and other studies to confirm that type and time
of congenital infection have no effect on subsequent handicaps. A
study in an area of high prevalence of congenital CMV, resulting
from maternal reactivation, may be required to study this aspect.
The frequency of reactivation and the precipitating factors are
still little understood particularly in relation to different rates
in different populations such as the Asian families in Britain,
Japan, and the black population of Alabama, USA. The effect of
improved affluence and other socioeconomic changes may become
evident as more second generation Asian women start to have
families in Britain.
It will be clear from this thesis that the biological
relationship between man and CMV is very complex and only by
detailed study of the epidemiology of CMV infection is it possible
to understand this relationship and plan methods of control of
infection and the prevention of significant neurological handicap
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Date of birth 1 I I I I I i 9-14
First day of last .—|—|—|—|—.—.
menstrual period ! I I I 1 I I '5-2C
{Put 99 (or day if not precisely remembered)
Previous pregnancies
Number of livebirths \ | 21
Number of stillbirths , | 22
Total number of previous .—.—.
pregnancies over 28 weeks I I | 23-24
Number of miscarriages 25
Number of terminations Q





Marital Status (tick relevant boxes) 27
single married divorced separated widowed cohabiting
□ □□□□□
Race 28
(for mixed race either tick two boxes or specify under other )
Asian Caucasian Negro Oriental Other Ispecifyl
□ □ □ □
Country of birth . 29-30
Occupation
For those in paid work please give 1) type of business or industry 2) actual work
done 3) level of responsibility.
For those not in paid work please state whether 1) never worked 2) student
3) housewife, or 4) unemployed at present in which case please state
unemployed' and then give details of last job as above.
Woman's occupation before home duties
.31-32
month year
Date left work or still working Q 33-36





CMV STUDY - INFANT'S DETAILS
Please complete this form at the infant's first possible examination, preferrably within the first 48 hours of life, and lend with a throat swab to the laboratory
Date of Birth:
Is this infant:




Use Mother's hospital sticker if available






Number of weeks gestation: .




j j Does the infant require special care? | | | [ 20





CHARING CROSS CMV STUDY
MATERNAL MASTER-CARD
(Maternal antenatal form to be stuck on here)
□Card 1:11 Serial No. 2-8
] 9-14 [ I I | jl 5-20 | 121
| |22| 1 [23-24 | |25 Ml 26 | |27 | |28
[ I 129-301 | [31-32MM 133-36 1 1 [37-38
Lab No: □
Blood 1











Collection date I I I I




CMV IF tit 11*
n l l 168-71
□ ?2
Card 2 : [7]l Serial No:
Blood 3




























(1 '• livehirth; 2 = stillbirth; 3 - neonatal death; 4 = spontaneous
































Age (at child's birth} .
Race












Age (at child's birth I _
Race
Country of birth _
Previous history:
Dm Fits 'f'BP Other Dm Fits ^BP Other
□»
Atopy Deafness? Psychomotor Atopy
retardation
I I« I U
Mother's history: this pregnancy
Smokes? BP 90D and/or proteinuria





Abroad during this pregnancy? If so, where?
and for how long? weeks 36-37
Presentation: Cephalic
(tick one) r~j


















□ □ □ □
18 19 20 21
I ^3 I \a E34
Q5
I U D7 C38
Q*
□ □ □ □














Mother's CMV status — cases only
1. Primary infection/seroconversion
2. Presumed primary infection (seropositive at booking, IgM positive)
□
□
3. Known reactivation (seropositive specimen before this pregnancy) | |
4. Presumed reactivation (seropositive at booking, IgM negative <d 12 weeks) | |








mm 42-44 Length at birth
48-49 at 1 minute, I 50-51 at 5 minutes Placental weight gms 52-54
Resuscitation
'
O2 by face mask | | for




RDS/TTN 24 hours | |so
Meconium aspirate | |61
Pneumonia [ ls2
Other | ;
Jaundice? Max. Bilirubin /imol/l 65-67 Hepatosplenomegaly? □ 68
CNS problems
Fits | |69











Was this child admitted to SCBU?| [so date .




























Chest examination □ 23
Heart: any abnormal sounds or murmurs? |' j
Femoral pulses
Abdomen: Liver | I26
Spleen | |27
Other
Genitalia [ [ 29
Skeletal abnormalities □ 30
CNS examination: state?
Fix follow □ Moro





! Tone symmetrical [ |










































Has the child been ill since last visit?
Do the parents think the child's
Hearing is normal | | ? | | abnormal □ ref. □ 25
Vision is normal | | ? | j abnormal | | ref. □ 26
Development










Self-care | | 1 43.44












Otitis media 1 1 '8 □ 19 o
URTI n20 □ 21 □2° D2'
LRTI n22 O □22 Q23






























Field- 1; POSTURE AND LARGE MOVEMENTS
a) Passive posture
1) Supine Position
Head to one side, knees apart 0
Head in midline 1
Lifts legs into vertical and grasps feet 2
2) Ventral Suspension
Head droops below plane of body, hips flexed,
limbs hang down 0
Head in line with body, hips semi-extended 1
Head above line of body, hips and shoulders
extended 2
3) Pull to sit
Marked head lag 0
Considerable head lag, when body vertical head held
momentarily erect before falling forwards 1
Little or no head lag 2
Braces shoulders and pulls self up 3
4) Sitting Position (Supported)
Back completely curved 0
Back fairly curved, intermittently holds head up 1
Back straight except in lumbar region, head
mostly held up 2
Back straight 3






Head sideways, hips and limbs extended 0
Head sideways resting on cheeks, buttocks high
with knees flexed under abdomen, arms close to
chest with elbows flexed 1
Head to side, limbs flexed, elbows away from body,
buttocks moderately high 2
Head to side, chin raised intermittently,
moderate extension of hips 3
Head and upper chest held up on forearms for
prolonged periods, buttocks flat 4
Head and chest well up, limbs stretched out in
'swimming' position 5
Supports weight on flattened palms and extended arras,
looks around alertly 6
Gets into crawling position 7
6) Sitting Position Not applicable 0
Sits alone momentarily, supports body on hands 1
Sits alone momentarily, without support 2
Sits alone for prolonged periods 3
Leans forwards or wideways to reach toy without
losing balance 4
Gets into sitting position from prone or supine 5
7) Rolling N/A 0
Rolls prone to supine 1
Rolls supine to prone 2
f?) Standing
Held standing sags at knees and bears on weight on
feet 0
Held standing bears some weight on feet 1
Held standing takes full weight on feet 2
Stands holding on 3




9) Locomotion N/A 00
Placing and stepping reflexes present
Progresses by rolling or squirming 01
Attempts to crawl (maybe backwards) 02
Crawls on hands and knees or shuffles on buttocks 03
Walks with hands held 04
Walks around furniture or pushing wheeled toy 05
Walks alone, feet wide apart, arms up for balance 06
Feet only slightly apart, can turn corners and
stop suddenly 07
Runs, cannot continue round obstacles 08
Picks up object from floor without falling 09
Runs confidently, stopping and starting with care
and avoiding obstacles 10
Jumps on both feet from low step 11
Can walk on tiptoe 12
Stands on one foot, runs on tiptoe 13
Skips, hops 14
10) Stairs
Crawls upstairs and may slither down backwards 1
Creeps backwards downstairs or bumps down on
buttocks facing forwards 2
Walks upstairs with hand held, two feet to a step 3
Walks up and down stairs confidently, two feet to
a step 4
Walks alone upstairs, one foot to a step, and down
two feet to a step 5
Walks alone up and down stairs, one foot to a step 6
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Field 2: VISION AND FINE MOVEMENTS
a) Manipulation
11) Hands
Hands loosely open 00
Hands closed and thumb turned in 01
Hand regard and finger play 02
Clasps hands and presses palms together 03
Palmar grasp using whole hand 04
Passes toy from one hand to the other 05
Holds two cubes, one in each hand and
brings them together 06
Picks up small object between finger and
thumb with 'inferior' pincer grasp 07
Neat pincer grasp between finger and thumb 08
Throws toys to the floor deliberately 09
Turns pages of a book, several at a time 10
Turns pages one at a time 11
Threads beads 12
Cuts with scissors 13
Bricks N/A 0
Tower of 2 1
Tower of 3 2
Tower of 4-6 3
Tower of 7+ 4
Copies bridge 5
6 cube steps 6
10 cube steps 7
13) Drawing N/A 0
To and fro scribble 1
Circular scribble 2
Imitates vertical and/or horizontal line 3
Imitates circle 4
Imitates cross 5
Draws man with head 6




14) Holds pencil in palmar grasp 1





No visual response 0
Turns towards diffuse light 1
Briefly follows torch light at 30 era. distance 2
Watches a face or dangling object in line of vision
and follows with eyes less than 90 3
Fixates on object and follows by turning head up
to 90° 4
o
Follows dangling object through 180 5
16) Visual comprehension N/A 0
Fixates on small objects and reaches out to
grasp thera 1
Watches falling toy and then forgets it 2
Looks in correct place for fallen toy 3
Watches movements of people at distance or out of
window with interest 4
Shows interest in pictures 5
Enjoys simple picture books and recognises
some items 6
Recognises fine detail in picture books 7
Matches two primary colours. Describes action
from picture 8
Matches and names four colours 9
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Field 3: HEARING AND SPEECH
a) Hearing
17) Auditory function
No auditory response 0
Startled by sudden noise 1
Responds to voice or gentle sound 2
Looks towards sound of mother.'s voice 3
18) Verbal comprehension N/A 0
Turns head towards sound source 1
Attentive to everyday sounds 2
Recognises own name 3
Hands over common objects on request 4
Understands simple phrases or questions S





Makes no sounds 0
Makes occasional grunting sounds 1
Vocalises when pleased 2
Laughs, chuckles and squeals in play 3
Babbles continuously and shouts to attract attention 4
Imitates adult's playful sounds, e.g. cough, b'rr
and smacking lips 5
20) Language N/A 00
Incessant Jargon containing most vowels and
many consonants 01
One word with meaning 02
Several words with meaning 03
Attempts to join in nursery rhyme 04
Puts two or more words together to form simple
sentences 05
Names familiar objects and pictures 06
Knows full name 07
Uses interrogative pronouns 'What?', Who?' and
personal pronouns *1, Me, You', correctly OS
Able to carry on simple conversation and describe
events 09
Tells stories with confabulation - big and small 10
Knows and repeats several nursery rhymes 11
Knows name and address, age and birthday - 12
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Field 4: SOCIAL BEHAVIOUR AND PLAY
a> Interactive Behaviour
24) Social Behaviour
Sleeps when not being fed or handled 00
Smiles to social stimulation 01
Responds with chuckles and excited movements
to friendly handling 02
Shy with strangers 03
Shows annoyance when frustrated 04
Plays 'pat-a-cake' and/or waves bye-bye 05
Restless and curious regarding people, objects
and events in immediate surroundings 06
Imitates simple everyday activities 07
Intensely curious regarding environment, little
comprehension of common dangers 08
Resistive and rebellious when thwarted 09
Plays with other children but will not share
toys 10
Understands sharing playthings and adults'
attention 11
Understands conception of present, past and
future 12
Takes turns and shares 13
Chooses own friends 14
25) Play
No interative paly 00
When offered rattle, reaches for it and
shakes to make it sound 01
Plays 'peek-a-boo' 02
Finds toy which is partially but not wholly
hidden 03
Puts bricks in and out of container when shown 04
Quickly finds hidden toy 05
Explores properties and possibilities of toys
and other objects with interest 06
Plays contentedly alone near familar person 07
Pushes and pulls large toys skilfully 08
Kicks large ball 09
Throws small ball overhand. Catches large ball 10
Rides tricyle well 11
Climbs trees, ladders. Make believe play 12
Plays ball games with rules 13
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b) Personal self-care behaviour
21) Feeding
No active response to bottle or spoon feeding
Puts hand to bottle when feeding
Tries to grasp spoon
Holds, bites and chews a biscuit
Drinks from a cup with assistance
Holds spoon and brings it to mouth but cannot
prevent it turning over
Holds cup with both hands and drinks without
too much spilling
Holds spoon and gets food safely to mouth
Lifts cup, drinks and replaces it on table
without difficulty
Eats skilfully with spoon
Eats with fork and spoon
Eats with knife and fork
22) Dressing
Passive acceptance of dressing routine
Holds up arms when being dressed or undressed
Helps constructively with dressing by holding
out arms and legs appropriately
Takes off shoes, socks or hat
Puts on hat and shoes
Pulls down pants or knickers
Can pull up pants or knickers
Can dress and undress, but not buttons and
laces
Can manage buttons and laces
23) Toilet
In nappies. No awareness of wetting/soiling
Indicates wet or soiled pants




Verbalises toilet needs in reasonable time
Usually dry at night if lifted
Washes hands
Brushes teeth

































Additional items for older children
Reel Toe standing I | 60





Draw a man below Scribble = 1
Head +1 =2
Head +3-4 = 3
Head +5-6 = 4
Read +7 =5
Jump and clap [ ! 61
Matchsticks □ 62
{ 1Pinboard L ft P. hands ! i j <33
Bridge of bricks '! j 65
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